WO2012092663A1 - Monoclonal anti-anti-anti-mhc antibodies and uses thereof - Google Patents
Monoclonal anti-anti-anti-mhc antibodies and uses thereof Download PDFInfo
- Publication number
- WO2012092663A1 WO2012092663A1 PCT/CA2012/000002 CA2012000002W WO2012092663A1 WO 2012092663 A1 WO2012092663 A1 WO 2012092663A1 CA 2012000002 W CA2012000002 W CA 2012000002W WO 2012092663 A1 WO2012092663 A1 WO 2012092663A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibodies
- mhc
- monoclonal
- animal
- donor
- Prior art date
Links
- 238000002054 transplantation Methods 0.000 claims abstract description 37
- 238000000034 method Methods 0.000 claims abstract description 34
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 23
- 238000011282 treatment Methods 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 10
- 241001465754 Metazoa Species 0.000 claims description 48
- 108091007433 antigens Proteins 0.000 claims description 48
- 102000036639 antigens Human genes 0.000 claims description 48
- 239000000427 antigen Substances 0.000 claims description 47
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 33
- 230000002163 immunogen Effects 0.000 claims description 28
- 210000004698 lymphocyte Anatomy 0.000 claims description 26
- 210000004408 hybridoma Anatomy 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 9
- 230000003053 immunization Effects 0.000 claims description 9
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 8
- 241000894007 species Species 0.000 claims description 8
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 5
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 abstract description 45
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 14
- 208000035475 disorder Diseases 0.000 abstract description 10
- 230000003412 degenerative effect Effects 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 52
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 52
- 210000001519 tissue Anatomy 0.000 description 52
- 210000001744 T-lymphocyte Anatomy 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 32
- 102000000479 TCF Transcription Factors Human genes 0.000 description 28
- 108010016283 TCF Transcription Factors Proteins 0.000 description 28
- 210000000987 immune system Anatomy 0.000 description 26
- 210000002966 serum Anatomy 0.000 description 25
- 210000003491 skin Anatomy 0.000 description 24
- 230000028993 immune response Effects 0.000 description 19
- 241000725303 Human immunodeficiency virus Species 0.000 description 17
- 230000007246 mechanism Effects 0.000 description 10
- 210000002540 macrophage Anatomy 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 206010018338 Glioma Diseases 0.000 description 8
- 206010025323 Lymphomas Diseases 0.000 description 8
- 208000003174 Brain Neoplasms Diseases 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 208000032612 Glial tumor Diseases 0.000 description 6
- 206010052779 Transplant rejections Diseases 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 208000032839 leukemia Diseases 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 230000006641 stabilisation Effects 0.000 description 6
- 238000011105 stabilization Methods 0.000 description 6
- 206010039491 Sarcoma Diseases 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 230000003302 anti-idiotype Effects 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 201000005962 mycosis fungoides Diseases 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 206010003571 Astrocytoma Diseases 0.000 description 4
- 208000021309 Germ cell tumor Diseases 0.000 description 4
- 208000007465 Giant cell arteritis Diseases 0.000 description 4
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 4
- 206010034277 Pemphigoid Diseases 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 230000002267 hypothalamic effect Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 3
- 206010021263 IgA nephropathy Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 description 3
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 3
- 208000034578 Multiple myelomas Diseases 0.000 description 3
- 206010038389 Renal cancer Diseases 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
- 230000036436 anti-hiv Effects 0.000 description 3
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 3
- 230000005784 autoimmunity Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 208000002458 carcinoid tumor Diseases 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000004153 islets of langerhan Anatomy 0.000 description 3
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 201000010982 kidney cancer Diseases 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 208000025113 myeloid leukemia Diseases 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 201000000849 skin cancer Diseases 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 201000008205 supratentorial primitive neuroectodermal tumor Diseases 0.000 description 3
- 206010043207 temporal arteritis Diseases 0.000 description 3
- 208000008732 thymoma Diseases 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 210000000239 visual pathway Anatomy 0.000 description 3
- 230000004400 visual pathway Effects 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 208000008190 Agammaglobulinemia Diseases 0.000 description 2
- 206010060971 Astrocytoma malignant Diseases 0.000 description 2
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 2
- 206010004593 Bile duct cancer Diseases 0.000 description 2
- 206010005949 Bone cancer Diseases 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 206010007275 Carcinoid tumour Diseases 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 208000015943 Coeliac disease Diseases 0.000 description 2
- 201000009273 Endometriosis Diseases 0.000 description 2
- 206010014967 Ependymoma Diseases 0.000 description 2
- 208000012468 Ewing sarcoma/peripheral primitive neuroectodermal tumor Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 2
- 206010061252 Intraocular melanoma Diseases 0.000 description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 description 2
- 208000012309 Linear IgA disease Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 206010025557 Malignant fibrous histiocytoma of bone Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000000172 Medulloblastoma Diseases 0.000 description 2
- 208000027530 Meniere disease Diseases 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 description 2
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 208000009359 Sezary Syndrome Diseases 0.000 description 2
- 208000021388 Sezary disease Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 208000006045 Spondylarthropathies Diseases 0.000 description 2
- 206010042276 Subacute endocarditis Diseases 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 201000005969 Uveal melanoma Diseases 0.000 description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000000781 anti-lymphocytic effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 201000007335 cerebellar astrocytoma Diseases 0.000 description 2
- 208000030239 cerebral astrocytoma Diseases 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 201000010002 cicatricial pemphigoid Diseases 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 208000024519 eye neoplasm Diseases 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 208000029824 high grade glioma Diseases 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 210000000244 kidney pelvis Anatomy 0.000 description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 208000030883 malignant astrocytoma Diseases 0.000 description 2
- 201000011614 malignant glioma Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
- 208000018795 nasal cavity and paranasal sinus carcinoma Diseases 0.000 description 2
- 208000008795 neuromyelitis optica Diseases 0.000 description 2
- 201000008106 ocular cancer Diseases 0.000 description 2
- 201000002575 ocular melanoma Diseases 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 201000005671 spondyloarthropathy Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000008467 subacute bacterial endocarditis Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 description 2
- 208000018417 undifferentiated high grade pleomorphic sarcoma of bone Diseases 0.000 description 2
- 210000000626 ureter Anatomy 0.000 description 2
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 description 1
- 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 description 1
- 208000032194 Acute haemorrhagic leukoencephalitis Diseases 0.000 description 1
- 206010001029 Acute pulmonary oedema Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 241000321096 Adenoides Species 0.000 description 1
- 208000002485 Adiposis dolorosa Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 208000001839 Antisynthetase syndrome Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 206010073360 Appendix cancer Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 206010071576 Autoimmune aplastic anaemia Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 description 1
- 206010069002 Autoimmune pancreatitis Diseases 0.000 description 1
- 208000022106 Autoimmune polyendocrinopathy type 2 Diseases 0.000 description 1
- 201000002827 Balo concentric sclerosis Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000009766 Blau syndrome Diseases 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006585 Bunion Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 201000002829 CREST Syndrome Diseases 0.000 description 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
- 206010007281 Carcinoid tumour of the stomach Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241001466804 Carnivora Species 0.000 description 1
- 208000005024 Castleman disease Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000024699 Chagas disease Diseases 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- 208000010007 Cogan syndrome Diseases 0.000 description 1
- 208000011038 Cold agglutinin disease Diseases 0.000 description 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010252 Concentric sclerosis Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
- 208000008743 Desmoplastic Small Round Cell Tumor Diseases 0.000 description 1
- 206010064581 Desmoplastic small round cell tumour Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 description 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
- 208000024134 Diffuse cutaneous systemic sclerosis Diseases 0.000 description 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
- 208000021866 Dressler syndrome Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000004332 Evans syndrome Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 208000017259 Extragonadal germ cell tumor Diseases 0.000 description 1
- 206010068715 Fibrodysplasia ossificans progressiva Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 108010052199 HLA-C Antigens Proteins 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 206010019939 Herpes gestationis Diseases 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 208000031814 IgA Vasculitis Diseases 0.000 description 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 208000000209 Isaacs syndrome Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 208000034624 Leukocytoclastic Cutaneous Vasculitis Diseases 0.000 description 1
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 1
- 206010024434 Lichen sclerosus Diseases 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 208000000185 Localized scleroderma Diseases 0.000 description 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 208000009777 Majeed syndrome Diseases 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 206010064281 Malignant atrophic papulosis Diseases 0.000 description 1
- 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 description 1
- 206010073059 Malignant neoplasm of unknown primary site Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 206010027982 Morphoea Diseases 0.000 description 1
- 201000002795 Muckle-Wells syndrome Diseases 0.000 description 1
- 206010028424 Myasthenic syndrome Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- 206010072359 Neuromyotonia Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 208000005225 Opsoclonus-Myoclonus Syndrome Diseases 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 206010033268 Ovarian low malignant potential tumour Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010053869 POEMS syndrome Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010048705 Paraneoplastic cerebellar degeneration Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000004788 Pars Planitis Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 208000008223 Pemphigoid Gestationis Diseases 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 206010035052 Pineal germinoma Diseases 0.000 description 1
- 206010050487 Pinealoblastoma Diseases 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 208000000766 Pityriasis Lichenoides Diseases 0.000 description 1
- 206010048895 Pityriasis lichenoides et varioliformis acuta Diseases 0.000 description 1
- 201000008199 Pleuropulmonary blastoma Diseases 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
- 208000031732 Post-Lyme Disease Syndrome Diseases 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000037534 Progressive hemifacial atrophy Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 208000003670 Pure Red-Cell Aplasia Diseases 0.000 description 1
- 206010071141 Rasmussen encephalitis Diseases 0.000 description 1
- 208000004160 Rasmussen subacute encephalitis Diseases 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 201000010848 Schnitzler Syndrome Diseases 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241001493546 Suina Species 0.000 description 1
- 208000002286 Susac Syndrome Diseases 0.000 description 1
- 208000010265 Sweet syndrome Diseases 0.000 description 1
- 208000027522 Sydenham chorea Diseases 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 201000009365 Thymic carcinoma Diseases 0.000 description 1
- 206010051526 Tolosa-Hunt syndrome Diseases 0.000 description 1
- 206010044407 Transitional cell cancer of the renal pelvis and ureter Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000025851 Undifferentiated connective tissue disease Diseases 0.000 description 1
- 208000017379 Undifferentiated connective tissue syndrome Diseases 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 208000006110 Wiskott-Aldrich syndrome Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 210000002534 adenoid Anatomy 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003409 anti-rejection Effects 0.000 description 1
- 230000001494 anti-thymocyte effect Effects 0.000 description 1
- 108010076945 antigen-specific helper factors Proteins 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 208000021780 appendiceal neoplasm Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 201000004984 autoimmune cardiomyopathy Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 208000027625 autoimmune inner ear disease Diseases 0.000 description 1
- 201000004339 autoimmune neuropathy Diseases 0.000 description 1
- 201000005011 autoimmune peripheral neuropathy Diseases 0.000 description 1
- 201000011385 autoimmune polyendocrine syndrome Diseases 0.000 description 1
- 201000009780 autoimmune polyendocrine syndrome type 2 Diseases 0.000 description 1
- 206010071572 autoimmune progesterone dermatitis Diseases 0.000 description 1
- 201000004982 autoimmune uveitis Diseases 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000008873 bone osteosarcoma Diseases 0.000 description 1
- 208000012172 borderline epithelial tumor of ovary Diseases 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 201000002143 bronchus adenoma Diseases 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 201000008522 childhood cerebral astrocytoma Diseases 0.000 description 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000019069 chronic childhood arthritis Diseases 0.000 description 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 201000003056 complement component 2 deficiency Diseases 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 208000018261 cutaneous leukocytoclastic angiitis Diseases 0.000 description 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000005115 demineralization Methods 0.000 description 1
- 230000002328 demineralizing effect Effects 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 208000002980 facial hemiatrophy Diseases 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 201000001505 hemoglobinuria Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 208000002557 hidradenitis Diseases 0.000 description 1
- 201000007162 hidradenitis suppurativa Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 201000006362 hypersensitivity vasculitis Diseases 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 201000008319 inclusion body myositis Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 210000000716 merkel cell Anatomy 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 208000037970 metastatic squamous neck cancer Diseases 0.000 description 1
- 206010063344 microscopic polyangiitis Diseases 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000017869 myelodysplastic/myeloproliferative disease Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 208000022982 optic pathway glioma Diseases 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 208000021284 ovarian germ cell tumor Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 201000005580 palindromic rheumatism Diseases 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002530 pancreatic endocrine carcinoma Diseases 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 201000007315 pineal gland astrocytoma Diseases 0.000 description 1
- 201000004838 pineal region germinoma Diseases 0.000 description 1
- 201000003113 pineoblastoma Diseases 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 208000010626 plasma cell neoplasm Diseases 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000009169 relapsing polychondritis Diseases 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 208000030859 renal pelvis/ureter urothelial carcinoma Diseases 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 208000037969 squamous neck cancer Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 208000009174 transverse myelitis Diseases 0.000 description 1
- 208000029387 trophoblastic neoplasm Diseases 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4216—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig
- C07K16/4225—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig against anti-HIV Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
- C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Definitions
- This disclosure relates, at least in part, to monoclonal antibodies and uses thereof.
- the present antibodies include monoclonal anti-anti-anti-MHC antibodies.
- the uses may include the facilitation of organ transplantation, the treatment of degenerative disorders including autoimmune diseases and cancers, and the like.
- the present disclosure further relates to compositions, uses, methods, systems, processes, kits, antibodies, and the like.
- Monoclonal antibodies are important both as a tool in biotechnology and for therapeutic purposes as biological pharmaceuticals.
- transplantation of organs, tissues or cells from one genetically distinct person (donor) to another (recipient) is relatively commonplace, a shortage of acceptable donors and immunologic rejection of the donated tissue by the recipient remain major hindrances. It is understood that the rejection of a donor's tissue involves both cellular and humoral mechanisms, mediated respectively by T cells and antibodies.
- the recipient's immune system especially targets histocompatibility antigens on the transplanted cells that are not seen as "self but rather as foreign entities.
- the donor's histocompatibility antigens will not completely match the recipient's histocompatibility antigens, and the recipient's immune system will almost certainly react to the incompatible donor's organs, tissues or cells.
- MHC histocompatibility complex
- HLA human leukocyte antigens
- the donor and recipient are not genetically identical resulting in some degree of rejection to the transplanted tissue.
- efforts are routinely made to find the best match between donor and recipient.
- Even in the best case scenario there is still a high probability that the minor histocompatibility antigens differ (and likely the major HLA antigens as well), and the donor and recipient will almost certainly be sufficiently distinct in terms of cellular antigens, which results in some degree of graft rejection.
- a negative cross-match indicates a recipient has antibodies against the red blood cells of the donor, in which case the donor cannot donate tissue or cells to the recipient without the recipient's immune system responding. Due partly to these negative cross-matches, only a small percentage of available donor-organs or donor-tissues are actually suitable for any given potential recipient.
- transplantation If transplantation is carried out, the adverse reactions following transplantation of an organ or tissue from one genetically distinct individual to another can cause difficulties.
- immunologic rejection of a transplanted organ or tissue can be particularly dangerous if the organ is life-sustaining, such as a heart, liver or lung. The destruction of such an organ may lead directly to the death of the patient.
- the quality of life of the recipient can be adversely affected by rejection of transplanted tissues such as insulin-producing pancreatic islet cells or kidneys.
- agents and therapies include: (1) corticosteroids, such as prednisone; (2) cytotoxic drugs, such as azathioprine and cyclophosphamide; (3) x-ray irradiation therapy; (4) anti-lymphocyte and anti-thymocyte globulins; (5) cyclosponne; and (6) monoclonal antibodies, such as OKT3, which reacts specifically with the CD3 antigen-recognition structure of human T cells and blocks the T cell effector function involved in allograft rejection.
- agents and therapies are all administered post-transplant and introduce their own undesirable side effects.
- immunosuppressive drugs such as prednisone and cyclosponne, are globally
- immunosuppressive which greatly increases the susceptibility of the recipient to serious infections and also increases the susceptibility of the recipients to opportunistic infections, against which normal individuals have strong defenses.
- High doses of corticosteroids may also cause cataracts, precipitate diabetes mellitus and hypertension, and/or cause
- Cyclosponne may cause hypertension, tremors, anorexia and elevated low-density lipoprotein levels. It also has major toxic effects on the kidney, which may lead to decreased renal function. Cytotoxic agents may cause anemia and thrombocytopenia and sometimes hepatitis. The anti- lymphocyte globulins may cause fever, hypotension, diarrhea, or sterile meningitis. OKT3 may cause chills and fever, nausea, vomiting, dianhea, rash, headache, photophobia and occasional episodes of life- threatening acute pulmonary edema.
- Xenografts herein defined as transplants from another species, could potentially resolve the shortage of transplantable organs and tissues. Xenografts have been used in the past for short term life support when a recipient urgently requires a transplant and no suitable donor is available. Such uses, however, have only been temporary measures to provide additional time to locate a suitable human donor.
- the potential use of xenografts as long-term grafts for human recipients is limited by the same major issues that affect allografts; i.e., rejection of the donor graft and the adverse effects of anti-rejection treatments. The problem of rejection is even heightened with xenografts as the risk of rejection of xenografts is considered to be even greater than for allografts.
- the present disclosure describes monoclonal anti-anti-anti-MHC antibodies.
- the present disclosure describes methods of production of anti-anti-anti-MHC antibodies.
- the present disclosure describes uses of monoclonal anti-anti-anti-MHC antibodies.
- the present disclosure describes a use monoclonal anti-anti-anti-MHC antibodies in the treatment of degenerative diseases including autoimmune diseases and cancers.
- the present disclosure describes a use of antibodies in reducing a recipient's immune response to donated tissue.
- the present use comprises introducing monoclonal anti- anti-anti -(donor MHC) antibodies to the recipient's immune system.
- compositions comprising monoclonal anti- anti-anti-MHC antibodies.
- the present disclosure describes rodent monoclonal anti-anti-anti-MHC antibodies.
- the disclosure describes fragments of monoclonal anti-anti-anti-MHC antibodies.
- the present disclosure describes a method of producing rodent monoclonal anti-anti-anti-MHC antibodies.
- the present disclosurer describes a use of monoclonal anti-anti-anti-MHC antibodies to facilitate tissue donation between appropriate pairs of vertebrate organisms. For example, organ donation between spouses, other relatives, partners, or other individuals. Further, the present disclosure describes a means for preparing a vertebrate organism or organisms for possible tissue donation to another vertebrate, for example in situations where married or common-law spouses wish to donate organs to their spouse, is also desired. Each member of a couple could benefit from being made immunologically tolerant to the tissue of the other. Then each member would be available as an organ donor for the other, should the need arise. This would facilitate the use of living donors for transplantations.
- the present disclosure describes a use of monoclonal anti-anti-anti-MHC antibodies in making each member of a pair of vertebrate organisms ("partners")
- the present disclosure describes a method of supplying monoclonal anti-anti- anti-(donor MHC) antibodies suitable for administration to an organ recipient, the method comprising: a) receiving input parameters, said parameters comprising donor lymphocytes; b) obtaining, based on the input parameters, an appropriate monoclonal anti-anti- anti-(donor MHC) antibodies for facilitating the transplantation of tissue from said donor to a recipient; and c) distributing said monoclonal anti-anti-anti-(donor MHC) antibodies to the
- immune response means the production of antibodies and/or the induction of cell mediated immunity specific for an antigen, including especially the production of antibodies or the induction of cell mediated immunity specific for transplantation antigens.
- the term "facilitating transplantation” means reducing the risk of rejection of donated tissue by a recipient.
- the term will refer to reducing the chance of rejection of the organ by the recipient and a consequent improvement in the chances of the transplantation being successful.
- the facilitation can include inducing transplantation tolerance by the administration of monoclonal anti-anti-anti-(donor MHC) antibodies in non-immunogenic form to a prospective donor recipient. This may be together with the application of a prospective donor skin graft. This process can induce transplantation tolerance in the recipient with respect to donor tissue such as donor organs, and organ transplantation can be attempted as needed.
- idiotype means the unique set of antigenic determinants (or epitopes) of the V region of an antibody, lymphocyte receptor or specific T cell factor, wherein such idiotype can potentially induce the formation of anti-idiotypic antibodies.
- anti-idiotype means the V region of an antibody, lymphocyte receptor or specific T cell factor that is complementary to the V region of the respective idiotype.
- anti-anti-self antibody in an alloimmune serum is an antibody that binds to an idiotype in the converse alloimmune serum (see Figure 1).
- anti-anti-P antibodies in a P anti-Q serum bind specifically to anti-P and anti-anti-anti-P antibodies in a Q anti-P serum.
- Anti-anti-self antibodies for example anti-anti-P in Figure 1, are
- anti-anti-anti-MHC antibody in the context of a P anti-Q immune response, where P and Q are vertebrates, means an antibody present in a P anti-Q serum, or a monoclonal antibody, that binds to the V regions of the anti-anti-Q antibodies present in a Q anti-P serum, but does not substantially bind to vertebrate Q MHC antigens (see Figure 1).
- anti-anti-anti-Q antibodies may be anti-anti-anti-(Q MHC).
- Hybridomas that produce monoclonal anti-anti-anti-donor antibodies can be selected using alloimmune animals on the basis of their V regions having complementarity to anti-anti- donor antibodies without substantially binding to donor MHC antigens. These anti-anti-anti- MHC antibodies are believed to bind in ELISA assays to HIV antigens, and it is believed that hybridomas that make monoclonal anti-anti-anti-MHC antibodies can be selected using alloimmune animals and selecting hybridomas with V regions that bind to HIV antigens.
- an animal P that has made an anti-Q immune response where P and Q are vertebrates, is "conversely alloimmune" to an animal Q that has made an anti-P immune response.
- the term "converse alloimmune serum” for a P anti-Q serum is a Q anti-P antiserum.
- the term “monoclonal anti-anti-anti-graft antibody” is synonymous with “monoclonal anti-anti-anti-(donor MHC) antibody”.
- HIV is the human immunodeficiency virus, including especially the HIV-1 human immunodeficiency virus.
- monoclonal donor-specific anti-HIV antibodies means monoclonal antibodies that are obtained by immunizing a vertebrate with donor lymphocytes and selecting hybridomas with V regions that bind to HIV antigens.
- non-immunogenic means delivery in a manner that does not induce significant production of antibodies that bind to the monoclonal anti-anti-anti-MHC antibodies being administered.
- the delievery may be without an adjuvant, via a non-immunogenic route, and/or in non-immunogenic amounts.
- anti-anti-(donor MHC) antibody means an anti-idiotype antibody that is present in an alloimmune serum and that is directed against the idiotypes of anti-(donor MHC) antibodies and anti-(donor MHC) T cell receptors that are present in the converse antiserum, and can recognize and interact with anti-(donor MHC) antibodies and anti-(donor MHC) T cell receptors that are present in the converse antiserum.
- the term "recipient” refers to a vertebrate organism which receives transplanted tissue from a genetically distinct organism.
- the term "donor” refers to a vertebrate organism from which tissue is removed or otherwise derived by, for example, tissue culturing techniques, and introduced into the recipient organism.
- the donor may be of the same (allograft) or different (xenograft) species.
- the term "catalyst animal” refers to a vertebrate organism that provides tissue, preferably lymphocytes, that is used for the immunization of a potential organ donor vertebrate, such that the donor makes an immune response that includes the production of anti-anti-donor antibodies.
- tissue means one or more nucleated cells. Frequently, the tissue will be from an organ such as, for example, skin, heart, lung, kidney, liver, spleen, thymus, lymph node, blood, bone marrow, pancreas, intestine, gall bladder, prostate, ovary, muscle, limbs, or the like. The tissue may be a whole or partial organ.
- Figure 1 shows a system by which anti-, anti-anti-, and anti-anti-anti- antibodies are defined and are believed to be present as polyclonal antibodies in alloimmune or
- a vertebrate "P” with MHC antigens P that is alloimmune or made alloimmune to a vertebrate "Q” with MHC antigens Q is believed to make anti-Q, anti-anti-P and anti-anti-anti-Q antibodies. If the vertebrate "Q" is alloimmune or is made alloimmune to the vertebrate "P", "Q” is believed to make anti-P, anti-anti-Q and anti-anti-anti-P antibodies.
- the anti-anti-Q antibodies in the Q anti-P serum are believed to have specificity for anti-Q and anti-anti-anti-Q polyclonal antibodies in the P anti-Q serum.
- the monoclonal anti-anti- anti-MHC antibodies of this invention are believed to have specificity for anti-anti-MHC antibodies without binding to MHC antigens, as shown here.
- Figure 2 illustrates the IJ phenomenon in the context of the symmetrical immune network theory.
- Figure 3 shows a possible mechanism for an anti-anti-(MHC class II) monoclonal antibody in immunogenic form being a vaccine for the prevention of infection with HIV.
- Figure 4 shows a possible mechanism for the induction of transplantation tolerance using anti-anti-(graft MHC) antibodies.
- Figure 5 shows a method for the induction of transplantation tolerance between two vertebrates P and Q using the immune system of a third party "catalyst" vertebrate C in the production of anti-anti-self polyclonal antibodies.
- Figure 6 shows a method for obtaining monoclonal anti-anti-anti-MHC antibodies and their use in a transplantation technology.
- Figure 7 shows a possible mechanism by which anti-anti-anti-(graft MHC) antibodies mediate transplantation tolerance.
- Figure 8 shows a possible mechanism for the stabilization of an immune system by monoclonal anti-anti-(self MHC) antibodies.
- Figure 9 shows a possible mechanism for the stabilization of an immune system by monoclonal anti-anti-anti-MHC antibodies.
- the present disclosure describes monoclonal anti-anti-anti-MHC antibodies and uses thereof.
- the present disclosure furthermore describes methods for the production of monoclonal anti-anti-anti-MHC antibodies and uses of monoclonal anti-anti-anti-MHC antibodies such as the treatment of degenerative disorders including autoimmune diseases and cancers.
- the immune system may be considered too active, and cancers may proliferate when the immune system is not active enough.
- the present disclosure describes a method of reducing the risk of the rejection of tissue transplanted into a recipient animal from a donor animal.
- the present disclosure provides a method of producing anti-idiotypic antibodies against antigen receptors on the surface of a recipient's lymphocytes and the use of such anti-idiotypic antibodies in preventing transplant rejection by a recipient by inducing a state of the recipient's immune system that is suppressed with regard to responding immunologically against the transplanted organ.
- the present disclosure further relates to compositions, uses, kits, and the like.
- the serum of an animal P that has been immunized with Q lymphocytes contains anti-Q, anti-anti-P, and anti-anti-anti-Q antibodies
- the serum of an animal Q that has been immunized with lymphocytes of an animal P contains anti-P, anti- anti-Q, and anti-anti-anti-P antibodies.
- the anti-anti-anti-P antibodies and anti-anti-anti-Q antibodies are called anti-IJ p and anti-IJ Q antibodies in mice.
- the diagonal lines in this diagram indicate that all of the specific antibodies induced in the P anti-Q serum have complementarity to antibodies in the Q anti-P serum.
- anti-anti-anti-MHC antibody in the context of an P anti-Q immune response, where P and Q are vertebrates, means an anti-anti-anti-(Q MHC) antibody, or a monoclonal antibody, that binds to the V regions of anti-anti-(Q MHC) antibodies present in a Q anti-P serum, but not to vertebrate Q MHC antigens.
- co-selection means the mutual positive selection of individual members from within two diverse populations, such that selection of members within each population is dependent on interaction with (recognition of) one or more members within the other population.
- Figure 2 shows how helper T cells and suppressor T cells are co-selected and can give rise to IJ determinants that are expressed on suppressor T cells. See Hoffinann, G. W. 1994. Immunol. Cell Biol, 72:338.
- FIG. 3 shows how monoclonal anti-anti-MHC antibodies in immunogenic form may induce an anti-anti-anti-MHC immune response that is also an anti-HIV immune response, and hence monoclonal anti-anti-MHC antibodies may function as a vaccine for protection against HIV infection. While not wishing to be bound by theory it is believed that HIV preferentially infects HIV-specific helper T cells (Hoffmann, G. W. 1994. Immunol. Cell Biol, 72:338-346; Douek D.K., et al. 2002. Nature, 417: 95-98), thus HIV could be selected to be similar to anti-anti-MHC antibodies.
- Immunization with protein antigens in immunogenic form can result in the production of antibodies that are both specific for the antigen and antiidiotypic. Hsu et al. (1989) Int. Immunol. 1, 197-204; Forsyth et al. (1990) J. Immunol. 145, 215-223. This dual specificity could mean an anti-anti-anti-MHC antibody may induce an anti-HIV immune response, and hence may also be effective as a vaccine in protection against HIV.
- V regions variable regions
- specific T cell factors specific lymphocyte receptors
- specific lymphocyte receptors recognize each other, and according to which such recognition is a key element in the regulation of the immune system.
- the V regions of antibodies, lymphocyte receptors and specific T cell factors each have a set of antigenic determinants (or epitopes) that characterize each type of antibody, receptor and specific T cell factor.
- idiotypes are referred to as idiotypes and function in their own right as antigenic stimuli, which can induce the formation of anti-idiotypic antibodies.
- An anti-idiotype is a set of antigenic determinants complementary to its respective idiotypes. The interactions between idiotypes and anti-idiotypes and the interaction between idiotypic receptors and anti-idiotypic receptors is thought to be a major factor in regulating a specific immune response (see, for example, Wigzell, H. and Binz, H. 1980. Progress in Immunology IV, eds. Fougereau, M. and Dausset, J. Academic Press, N.Y., p. 94-103; Infante, et al. 1982. J. Exp. Med.
- the present disclosure comprises obtaining monoclonal anti-anti-anti-MHC and/or fragments of monoclonal anti-anti-anti-MHC antibodies.
- These antibodies may be produced in any suitable method such methods being well known in the art. Preferred methods of producing monoclonal anti-anti-anti-MHC mAbs are described below in
- the present use of monoclonal anti-anti-anti-MHC antibodies comprises administering the antibodies to the recipient in non-immunogenic form.
- the dose of monoclonal anti-anti-anti-MHC antibodies is determined by one skilled in the art.
- the recipient is given monoclonal anti-anti-anti-(donor MHC) antibodies intravenously or intra-peritoneal without an adjuvant, in amounts preferably between about 10 ng and about 10 ⁇ g of anti-anti-(donor MHC) antibody per kilogram weight of the recipient per dose, even more preferably about 1 ⁇ of anti-anti-(donor MHC) antibody per kilogram of the recipient per dose.
- donor serum comprising anti-anti-(donor MHC) antibodies is administered to the recipient, which administration comprises: (i) obtaining serum or purified IgG antibodies from an immunized donor; (ii) adsorbing the donor's serum or purified IgG antibodies using recipient tissue in order to remove any anti-(recipient MHC) antibodies; and (iii) administering the resulting serum or purified IgG antibodies containing anti-anti-(donor MHC) activity to the recipient to facilitate acceptance of the donor's graft.
- FIG 4 shows how a possible mechanism for how anti-anti-graft antibodies, which are also known as anti-anti-(donor MHC) antibodies, are believed to facilitate the induction of transplantation tolerance.
- the anti-anti-graft antibodies when administered to the recipient, stimulate T cells of the recipient.
- the anti-anti-graft antibodies stimulate anti-anti- anti-graft T cells and anti-graft T cells, which causes the secretion of specific T cell factors.
- These T cell factors are protein molecules that are postulated to be monovalent (i.e., having only one V region).
- the V regions of specific T cell factors mediate the T cell factors' specificity. Since T cell factors are monovalent, T cell factors in soluble form cannot crosslink complementary receptors; however, such soluble T cell factors can be stimulatory when presented on the surface of non-specific accessory cells ("A cells”) including macrophages.
- a cells non-specific accessory cells
- the T cell factors that are secreted by the anti-anti-anti-graft T cells and anti-graft T cells have anti-anti-anti-graft specificity and anti-graft specificity. These T cell factors of a given specificity are adsorbed by and presented on the surface of macrophages.
- the surface of the macrophage is a highly immunogenic surface, and the presence of the specific T cell factors on the surface of macrophages stimulate T cells bearing receptors that are
- the anti-anti-anti-graft T cell factors and anti-graft T cell factors specifically stimulate anti-anti-graft T cells.
- These anti-anti-graft T cells secrete anti- anti-graft specific T cell factors, which in turn are presented on the surface of macrophages, resulting in the proliferation of anti-graft T cells and anti-anti-anti-graft T cells.
- the macrophages of the recipient become armed with a mixture of anti-graft, anti-anti- graft and anti-anti-anti-graft T cell factors.
- the immune system of the recipient goes into a state in which there are elevated levels of anti- graft, anti-anti-graft and anti-anti-anti-graft T cells, and their mutual stimulation leads to a significant level of these cells and their corresponding antigen-specific T cell factors.
- this is thought to be a specifically suppressed state for the recipient especially with regard to the MHC antigens of the organ donor.
- the recipient's immune system is therefore selectively suppressed with respect to any immunity against the antigens of the donor, while still leaving the remainder of the immune system intact and not injuring other important organs, tissues or cells.
- the present disclosure may involve a donor animal that is a different species from the recipient animal, i.e., a xenogeneic transplantation. Many species could potentially be used as donor animals and different animals offer advantages for select uses.
- donor animals are of the class Mammalia. Of the class Mammalia, five orders are particularly suitable for human recipients: primates, artiodactyls, carnivores, rodents, and lagamorphs.
- a potential transplant recipient receives either anti-anti-donor antibodies or monoclonal anti-anti-anti-donor antibodies.
- the antibodies may be given substantially simultaneously with the transplant. An additional dose or doses may be delivered at intervals thereafter.
- the antibodies may also be given prior to the transplant.
- the antibodies are given substantially simultaneously with a skin graft, and optionally at intervals thereafter.
- the anti-anti-donor or monoclonal anti-anti-anti-donor antibodies may also be given prior to the time of a skin graft.
- An embodiment of the present method involves immunizing a prospective organ donor A with tissue of a prospective transplant recipient B, preferably including lymphocytes.
- the prospective donor A is immunized with tissue of the organ recipient B.
- the tissue of the recipient used for the immunization is preferably lymphocytes.
- the tissue of the recipient used for immunization can be gamma irradiated, for example with 3000 rads of gamma irradiation.
- Polyclonal IgG obtained from the immunized donor can be absorbed using B tissue, for example B lymphocytes, removing the anti-B and anti-anti-anti-B antibodies, and leaving serum or IgG containing anti-anti-A antibodies.
- These polyclonal antibodies can be given to the potential organ recipient in non-immunogenic form preferably starting at the time point of a skin graft from the potential organ donor.
- Administration of the anti-anti-A antibodies may also be given prior to the time of skin tissue transplantation.
- the number of administrations that are needed may vary depending on circumstances but, for example, there may be two or more, three or more, four or more, ten or more, or twenty or more administrations of anti-anti-A antibodies.
- the administrations may be at any suitable time interval.
- the time between administrations may be initially relatively short, e.g. one or two days, then after a week or so the time intervals can be extended, e.g. doubled, and then systematically increased as needed.
- the dose in each given case can be varied depending on the response of the recipient. For example any inflammation at the site of the skin graft is indicative of the need for more doses of anti-anti-A antibodies or of larger doses of the anti-anti-A antibodies.
- the prospective organ recipient B is able to accept an organ transplant from the ogan donor A at any time that this is needed. This method allows for the induction of one way transplantation tolerance, since the donor A becomes immune to the tissue of the recipient B and cannot also be made transplantation tolerant with respect to tissue of the recipient.
- An embodiment of the present method involves the induction of reciprocal transplantation tolerance between two vertebrates, for example between two members of a couple A and B.
- This embodiment allows for both A and B to become potential organ donors for each other if and when the need should arise.
- This embodiment involves a third party catalyst vertebrate C as shown in Figure 5.
- Both A and B are immunized with tissue of C, preferably including lymphocytes.
- A makes anti-C, anti-anti-A and anti-anti-anti-C antibodies
- B makes anti-C, anti-anti-B and anti-anti-anti-C antibodies.
- the A and B immune sera are absorbed using C tissue to remove anti-C and anti-anti-anti-C antobodies, leaving anti-anti-A and anti-anti-B serum respectively.
- the anti-anti-A antibodies are administered in non-immunogenic form to B at the time of the application of a B skin graft and at intervals following the application of the skin graft.
- the anti-anti-B antibodies are administered in non-immunogenic form to A at the time of the application of a B skin graft and at intervals following the application of the skin graft.
- a and B are mutually transplantation tolerant with respect to the other, and each can receive an organ transplant from the other if and when needed.
- the skin grafts are stably accepted when there is no evidence of rejection within a suitable period, for example when the skin grafts have not been rejected and there is no inflammation at the site of the skin graft three months after the application of the skin graft.
- Figure 6 shows a method for obtaining monoclonal anti-anti-anti-MHC antibodies and their use in a transplantation technology.
- a vertebrate CI is immunized with lymphocytes of a vertebrate P and a vertebrate C2 is immunized with lymphocytes of a vertebrate Q.
- the B lymphocytes of vertebrate CI are used to make hybridomas.
- Hybridomas are selected that have V regions that bind to HIV antigens. These hybridomas make monoclonal HIV-specific anti-anti-anti-(P MHC) antibodies.
- the B lymphocytes of vertebrate C2 are used to make hybridomas.
- Hybridomas are selected that have V regions that bind to HIV antigens.
- hybridomas make monoclonal HIV-specific anti-anti-anti-(Q MHC) antibodies.
- P receives a Q skin graft together with anti-anti-anti-Q antibodies and Q receives a P skin graft together with anti-anti-anti-P antibodies.
- Q receives a P skin graft together with anti-anti-anti-P antibodies.
- Figure 7 shows a possible mechanism by which monoclonal anti-anti-anti-graft MHC antibodies mediate transplantation tolerance.
- Alpha (a) is an abbreviation for "anti-” and "tab” means specific T cell factor.
- Small doses of the anti-anti-anti-graft antibodies in non- immunogenic form stimulate anti-anti-graft T cells that secrete anti-anti-graft specific T cell factors (tabs).
- These specific T cell factors bind to the surface of non-specific accessory cells including macrophages (A cells), where they present an array that is stimulatory for anti-graft T cells and anti-anti-anti-graft T cells that secrete anti-graft tabs and anti-anti-anti-graft tabs respectively.
- the A cells thus become armed with a mixture of anti-graft, anti-anti-graft and anti-anti-anti-graft tabs, and the immune system is stimulated to go to a state with elevated levels of anti-graft, anti-anti-graft and anti-anti-anti-graft T cells, which in the context of the symmetrical immune network theory is believed to be a specifically suppressed state with regard to making an immune response to the graft.
- Figure 8 shows a possible mechanism for the stabilization of an immune system by monoclonal anti-anti-(self MHC) antibodies. Such stabilization is for the prevention and treatment of degenerative diseases including autoimmunity and cancers.
- the Greek letter alpha (a) is an abbreviation for "anti-" and "tab” means specific T cell factor.
- Anti-anti-(self MHC) antibodies (aaself) stimulate aself and aaaself T cells.
- the aself T cells are also stimulated by the self.
- the aself and aaaself T cells secrete aself and aaaself tabs respectively.
- the aself and aaaself tabs bind to the surface of A cells.
- the a(self MHC) and aaaself tabs on the A cells stimulate aaself T cells.
- the aaself T cells secrete aaself tabs that also bind to the surface of A cells.
- the armed A cell stimulates the proliferation of aself, aaself and aaaself T cells.
- the resulting state of the system with elevated levels of aself, aaself and aaaself T cells is stabilized and is believed to be resistant against making immune responses against self, without being compromised regarding making immune responses to substances that cause a disease or disorder such as cancer cells.
- Figure 9 shows a possible mechanism for the stabilization of an immune system by monoclonal anti-anti-anti-MHC antibodies. Such stabilization is for the prevention and treatment of degenerative diseases including autoimmunity and cancers.
- Alpha (a) is an abbreviation for "anti-” and "tab” means specific T cell factor.
- Small doses of the anti-anti- anti-(self MHC) antibodies in non-immunogenic form stimulate anti-anti-self T cells that secrete anti-anti-self specific T cell factors (tabs).
- T cell factors bind to the surface of non-specific accessory cells including macrophages (A cells), where they present an array that is stimulatory for anti-self T cells and anti-anti-anti-self T cells that in turn secrete anti-self tabs and anti-anti-anti-self tabs respectively.
- a cells thus become armed with a mixture of anti-self, anti-anti-self and anti-anti-anti-self tabs, and the immune system goes to a specifically stabilized state with regard to making immune responses against self, on account of an increase in the level of the centrally important anti-anti-self T cells, without being compromised regarding making immune responses to substances that cause a disease or disorder such as cancer cells.
- the monoclonal anti-anti-anti-MHC antibodies described herein can be used to prevent and/or treat degenerative disorders for example autoimmune disorders and cancers.
- Any suitable autoimmune disorder may be prevented, treated, or the prevention or treatment of the disorder may be aided with the present monoclonal anti-anti-anti-MHC antibodies.
- identified autoimmune disorders include, but are not limited to, Achlorhydra; Autoimmune Active Chronic Hepatitis; Acute Disseminated
- Autoimmune inner ear disease Autoimmune lymphoproliferative syndrome; Autoimmune peripheral neuropathy; Autoimmune pancreatitis; Autoimmune polyendocrine syndrome Types I, II, & III; Autoimmune progesterone dermatitis; Autoimmune thrombocytopenic purpura; Autoimmune uveitis; Balo disease/Balo concentric sclerosis; Bechets Syndrome; Berger's disease; Bickerstaff s encephalitis; Blau syndrome; Bullous Pemphigoid;
- Chronic inflammatory demyelinating polyneuropathy Chronic recurrent multifocal ostomyelitis; Chronic lyme disease; Chronic obstructive pulmonary disease; Churg-Strauss syndrome; Cicatricial Pemphigoid; Coeliac Disease; Cogan syndrome; Cold agglutinin disease; Complement component 2 deficiency; Cranial arteritis; CREST syndrome; Crohns Disease; Cushing's Syndrome; Cutaneous leukocytoclastic angiitis; Dego's disease; Dercum's disease; Dermatitis herpetiformis; Dermatomyositis; Diabetes mellitus type 1 ; Diffuse cutaneous systemic sclerosis; Dressler's syndrome; Discoid lupus erythematosus; Eczema; Endometriosis; Enthesitis-related arthritis; Eosinophilic fasciitis; Epidermolysis bullosa acquisita; Erythema nodo
- Fibrodysplasia ossificans progressiva; Fibromyalgia; Fibromyositis; Fibrosing aveolitis;
- Gastritis Gastrointestinal pemphigoid; Giant cell arteritis; Glomerulonephritis; Goodpasture's syndrome; Graves' disease; Guillain-Barre syndrome (GBS); Hashimoto's encephalitis;
- Hashimoto's thyroiditis Haemolytic anaemia; Henoch-Schonlein purpura; Herpes gestationis; Hidradenitis suppurativa; Hughes syndrome (Antiphospholipid syndrome);
- Idiopathic Inflammatory Demyelinating Diseases Idiopathic pulmonary fibrosis; Idiopathic thrombocytopenic purpura (Autoimmune thrombocytopenic purpura); IgA nephropathy (Berger's disease); Inclusion body myositis; Inflammatory demyelinating polyneuopathy; Interstitial cystitis; Irritable Bowel Syndrome (IBS); Juvenile idiopathic arthritis; Juvenile rheumatoid arthritis; Kawasaki's Disease; Lambert-Eaton myasthenic syndrome; Leukocytoclastic vasculitis; Lichen planus; Lichen sclerosus; Linear IgA disease (LAD); Lou Gehrig's Disease (Amyotrophic lateral sclerosis); Lupoid hepatitis; Lupus erythematosus; Majeed syndrome; Meniere's disease; Microscopic polyangiitis;
- Miller-Fisher syndrome Mixed Connective Tissue Disease; Morphea; Mucha-Habermann disease; Muckle- Wells syndrome; Multiple Myeloma; Multiple Sclerosis; Myasthenia gravis; Myositis; Narcolepsy; Neuromyelitis optica (Devic's Disease); Neuromyotonia; Occular cicatricial pemphigoid; Opsoclonus myoclonus syndrome; Ord thyroiditis; Palindromic rheumatism; PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus); Paraneoplastic cerebellar degeneration; Paroxysmal nocturnal
- hemoglobinuria PNH
- Parry Romberg syndrome Parsonnage- Turner syndrome
- Pars planitis Pemphigus; Pemphigus vulgaris; Pernicious anaemia; Perivenous encephalomyelitis; POEMS syndrome; Polyarteritis nodosa; Polymyalgia rheumatica; Polymyositis; Primary biliary cirrhosis; Primary sclerosing cholangitis; Progressive inflammatory neuropathy;
- Psoriasis Psoriatic Arthritis; Pyoderma gangrenosum; Pure red cell aplasia; Rasmussen's encephalitis; Raynaud phenomenon; Relapsing polychondritis; Reiter's syndrome; Restless leg syndrome; Retroperitoneal fibrosis; Rheumatoid arthritis; Rheumatoid fever; Sarcoidosis; Schizophrenia; Schmidt syndrome; Schnitzler syndrome; Scleritis; Scleroderma; Sjogren's syndrome; Spondyloarthropathy; Sticky blood syndrome; Still's Disease; Stiff person syndrome; Subacute bacterial endocarditis (SBE); Susac's syndrome; Sweet syndrome;
- SBE Subacute bacterial endocarditis
- Sydenham Chorea Sympathetic ophthalmia; Takayasu's arteritis; Temporal arteritis (Giant cell arteritis); Tolosa-Hunt syndrome; Transverse Myelitis; Ulcerative Colitis; Undifferentiated connective tissue disease; Undifferentiated spondyloarthropathy; Vasculitis; Vitiligo; Wegener's granulomatosis; Wilson's syndrome; Wiskott-Aldrich syndrome.
- Any suitable cancer may be prevented, treated, or the prevention or treatment of the cancer may be aided with the present monoclonal anti-anti-anti-MHC antibodies.
- identified or suspected cancers include, but are not limited to, Acute lymphoblastic leukemia; Acute myeloid leukemia; Adrenocortical carcinoma; AIDS-related cancers; AIDS- related lymphoma; Anal cancer; Appendix cancer; Astrocytoma, childhood cerebellar or cerebral; Basal cell carcinoma; Bile duct cancer, extrahepatic; Bladder cancer; Bone cancer, Osteosarcoma/Malignant fibrous histiocytoma; Brainstem glioma; Brain tumor; Brain tumor, cerebellar astrocytoma; Brain tumor, cerebral astrocytoma/malignant glioma; Brain tumor, ependymoma; Brain tumor, medulloblastoma; Brain tumor, supratentorial primitive neuroectodermal tumors; Brain tumor
- Cutaneous T-cell lymphoma Desmoplastic small round cell tumor; Endometrial cancer; Ependymoma; Esophageal cancer; Ewing's sarcoma in the Ewing family of tumors;
- Extracranial germ cell tumor Childhood; Extragonadal Germ cell tumor; Extrahepatic bile duct cancer; Eye Cancer, Intraocular melanoma; Eye Cancer, Retinoblastoma; Gallbladder cancer; Gastric (Stomach) Cancer; Gastric (Stomach) Cancer, Childhood; Gastrointestinal Carcinoid Tumor; Gastrointestinal Stromal Tumor (GIST); Germ Cell Tumor, Extracranial, Childhood; Germ Cell Tumor, Extragonadal; Germ Cell Tumor, Ovarian; Gestational Trophoblastic Tumor; Glioma, Adult; Glioma, Childhood Brain Stem; Glioma, Childhood Cerebral Astrocytoma; Glioma, Childhood Visual Pathway and Hypothalamic; Gastric Carcinoid; Hairy cell leukemia; Head and neck cancer; Heart cancer; Hepatocellular (liver) cancer; Hodgkin lymphoma; Hypopharyngeal cancer; Hypothalamic and
- Nasopharyngeal carcinoma Neuroblastoma; Non-Hodgkin lymphoma; Non-small cell lung cancer; Oral Cancer; Oropharyngeal cancer; Osteosarcoma/malignant fibrous histiocytoma of bone; Ovarian cancer; Ovarian epithelial cancer (Surface epithelial-stromal tumor); Ovarian germ cell tumor; Ovarian low malignant potential tumor; Pancreatic cancer; Pancreatic cancer, islet cell; Paranasal sinus and nasal cavity cancer; Parathyroid cancer; Penile cancer; Pharyngeal cancer; Pheochromocytoma; Pineal astrocytoma; Pineal germinoma;
- nonmelanoma Squamous neck cancer with occult primary, metastatic; Stomach cancer; Supratentorial primitive neuroectodermal tumor, childhood; T-Cell lymphoma, cutaneous (Mycosis Fungoides and Sezary syndrome); Testicular cancer; Throat cancer; Thymoma, childhood; Thymoma and Thymic carcinoma; Thyroid cancer; Thyroid cancer, childhood; Transitional cell cancer of the renal pelvis and ureter; Trophoblastic tumor, gestational;
- Unknown primary site carcinoma of, adult; Unknown primary site, cancer of, childhood; Ureter and renal pelvis, transitional cell cancer; Urethral cancer; Uterine cancer, endometrial; Uterine sarcoma; Vaginal cancer; Visual pathway and hypothalamic glioma, childhood;
- Vulvar cancer Waldenstrom macroglobulinemia
- Wilms tumor (kidney cancer), childhood.
- the present anti-anti-anti-MHC antibodies may aid in the treatment, prevention, and/or cure of other degenerative diseases or conditions. Such antibodies may act as immune system stabilizers. Examples of other degenerative diseases or conditions include, but are not limited to, acne, adenoid problems, AIDS, allergies, Alzheimer's disease, asthma,
- Atherosclerosis blisters, bronchitis, bunions, burns, canker sores, cataracts, celiac disease, cervical problems, cholesterol problems, chronic fatigue syndrome, chronic pain, circulatory problems, cirrhosis, cold sores, colitis, dermatitis, diverticulitis, eczema, emphysema, endometriosis, epilepsy, fever, gastritis, goiter, gout, hay fever, heart disease, haemorrhoids, hepatitis, hives, inflammation, itching skin, kidney disease, lactose intolerance, Meniere's disease, neuralgia, Parkinson's disease, pelvic inflammatory disease, phlebitis, pleurisy, pregnancy problems, premenstrual syndrome, prostate problems, rashes, sinusitis, tendonitis, thyroid problems, uterine problems, vaginal problems, varicose veins, and warts.
- the present disclosure provides the use of the monoclonal or polyclonal anti-anti-anti- graft or anti-anti-graft antibodies antibodies to reduce the risk of transplant rejection in a recipient by administering to the recipient animal an effective amount of monoclonal or polyclonal anti-anti-anti-graft or anti-anti-graft antibodies in a non-immunogenic form.
- administration of the compound according to the invention may be combined with more traditional and existing therapies for treating or preventing the disorder e.g. transplant rejection.
- an "effective amount" of a compound according to the invention refers to a non- immunogenic amount, for the number and periods of time necessary, to achieve the desired result; that is, selective suppression of the recipient's immune response to the donor graft.
- An effective amount of the compound may vary according to factors such as the health, age, sex and weight of the individual, and the species of the donor and recipient animals. The effective amount may be adjusted to provide the optimum result.
- the amount be between about 1 ng and about 10 ⁇ g of the monoclonal or polyclonal anti-anti-anti-graft or anti-anti-graft antibody per kilogram per administration to the recipient, or alloimmune immunogen absorbed serum containing approximately the same total amount of anti-anti- graft IgG.
- composition comprising the monoclonal or polyclonal anti-anti-anti-graft or anti-anti-graft antibody in combination with a
- the pharmaceutically acceptable carrier will depend on the mode of administration of the compound.
- the carrier may, for example, be non- immunogenic. Suitable carriers are those known in the art for use in such modes of administration.
- compositions may be formulated by means known in the art and their mode of administration.
- the pharmaceutical composition may comprise anti-anti-anti-MHC monoclonal or polyclonal antibodies or fragments of antibodies in combination with a pharmaceutically acceptable carrier.
- the dose of the pharmaceutical composition may be determined by the skilled practitioner. It is preferred that each dose contain between about 10 ng and about 10 ⁇ g of the monoclonal anti-anti-anti-graft antibody per kilogram weight of the recipient. For example, about 1 ⁇ g of the monoclonal or polyclonal anti-anti-anti-graft or anti-anti-MHC antibody per kilogram weight of the recipient per dose, or alloimmune immunogen absorbed serum containing the same total amount of IgG.
- the present invention further discloses a kit comprising a pharmaceutical composition of the monoclonal or polyclonal anti-anti-anti-MHC or anti-anti-MHC antibody with a pharmaceutically acceptable carrier together with instructions for administration to recipients of donor tissue.
- the present disclosure further provides a method of supplying monoclonal or polyclonal anti-anti-anti-MHC or anti-anti-MHC antibodies, the method comprising: a) receiving input parameters, said parameters comprising a sample of lymphocytes from a tissue donor and a delivery location; b) obtaining, based on the input parameters, an appropriate monoclonal or
- polyclonal anti-anti-anti-MHC or anti-anti-MHC antibodies for facilitating the transplantation of tissue from said donor to a recipient; and c) distributing said monoclonal or polyclonal anti-anti-anti-MHC or anti-anti-MHC antibodies to the delivery location.
- the present method can be used also for non-human vertebrates.
- the method may include the production of monoclonal or polyclonal anti-anti-anti-graft or anti- anti-graft antibodies suitable for using dogs as donors for dogs that are in need of an organ transplant, and the production of monoclonal or polyclonal anti-anti-anti-graft or anti-anti- graft antibodies suitable for using cats as donors for cats.
- the present method comprises distributing the antibodies to a delivery location.
- the distribution may be done by any suitable means. Given the time sensitivity of organ donation it is preferred that the distribution is performed in an expeditious manner.
- the present disclosure provides a method, use, pharmaceutical composition and kit for preventing rejection of a transplanted tissue from a donor.
- the present disclosure provides a highly efficacious way of attaining selective suppression of the recipient's immune system.
- administration of monoclonal or polyclonal anti-anti-anti- graft or anti-anti-graft antibodies obtained from an immunized donor can specifically and robustly suppress the immune response of the recipient against the foreign antigens of the transplanted graft, without comprising the immune response of the recipient against other antigens.
- the risk of adverse effects associated with immunosuppressant drugs currently used in preventing graft rejection is reduced.
- Transplantation of organs, tissues or cells from donors of a species different from that of the recipient may also be used as a long- term, sustainable therapy for organ or tissue failure.
- Example 1 A method for producing anti-anti-anti-MHC antibodies using the immune systems of two animals P and Q, whereby the anti-anti-anti-MHC antibodies are believed to be functionally the equivalent of anti-IJ p antibodies in mice.
- the method comprises the steps of: a. an animal P is multiply immunized with lymphocytes of an animal Q; b. an animal Q is multiply immunized with lymphocytes of an animal P;
- IgG is obtained from the said immunized animal P is absorbed using Q
- hybridomas are produced using B lymphocytes of the the immunized animal Q; e. hybridomas from step d. are selected that have V regions that bind to the V
- the hybridomas selected in step e. are used to make the monoclonal anti-anti-anti- (MHC P) antibodies.
- Example 2 A method for producing monoclonal anti-anti-anti-MHC antibodies, whereby the anti-anti-anti-MHC antibodies are believed to be functionally the equivalent of anti-IJ p antibodies in mice and are believed to bind to the HIV antigens gpl20, gp41 and p24.
- the method comprises the steps of: a. an animal Q is multiply immunized with lymphocytes of an animal P; b. lymphocytes of the immunized animal Q are used to make hybridomas; c. the hybridomas are used to produce monoclonal antibodies, which are assayed for binding to HIV antigens; d. the monoclonal antibodies that bind to the said HIV antigens are believed to be the desired anti-anti-anti-MHC antibodies.
- Example 3 The use of monoclonal anti-anti-anti-MHC antibodies in the treatment of a patient with an autoimmune disease comprising the administration of monoclonal anti-anti- anti-(patient MHC) antibodies in non-immunogenic form and in non-immunogenic amounts and a pharmaceutically acceptable carrier.
- Example 4 The use of monoclonal anti-anti-anti-MHC antibodies in the treatment of a patient with a cancer comprising the administration of monoclonal anti-anti-anti-(patient MHC) antibodies in non-immunogenic form and in non-immunogenic amounts and a pharmaceutically acceptable carrier.
- Example 5 The use of monoclonal anti-anti-anti-MHC antibodies in the treatment of the recipient of an organ transplant comprising the administration to the recipient of monoclonal anti-anti-anti-(donor MHC) antibodies in non-immunogenic form and in non- immunogenic amounts and a pharmaceutically acceptable carrier, where the donor is the donor of the organ, starting at the time of a skin graft, and at intervals thereafter, until the skin graft is stably accepted. Then the recipient is believed to be tolerant to tissue of the organ donor, and the organ transplant is carried out. Additional administrations of the anti-anti-anti- donor antibodies may optionally be given following the transplantation of the organ from the donor to the recipient.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
This disclosure relates, at least in part, to monoclonal antibodies and uses thereof. The present antibodies include monoclonal anti-anti-anti-MHC antibodies. The uses may include the facilitation of organ transplantation, the treatment of degenerative disorders including autoimmune diseases and cancers. The present disclosure further relates to compositions, uses, methods, systems, processes, kits, antibodies, and the like.
Description
MONOCLONAL ANTI-ANTI-ANTI-MHC ANTIBODIES AND USES THEREOF FIELD
[0001] This disclosure relates, at least in part, to monoclonal antibodies and uses thereof. The present antibodies include monoclonal anti-anti-anti-MHC antibodies. The uses may include the facilitation of organ transplantation, the treatment of degenerative disorders including autoimmune diseases and cancers, and the like. The present disclosure further relates to compositions, uses, methods, systems, processes, kits, antibodies, and the like.
BACKGROUND
[0002] Monoclonal antibodies are important both as a tool in biotechnology and for therapeutic purposes as biological pharmaceuticals.
[0003] Many diseases and conditions may be caused by the immune system not functioning optimally. These include, for example, autoimmune diseases in which case the immune system may be too active, and cancers in which case the immune system may not be sufficiently active. Immune system stabilizers that are effective in aiding in the treatment of such disorders would be useful.
[0004] Although transplantation of organs, tissues or cells from one genetically distinct person (donor) to another (recipient) is relatively commonplace, a shortage of acceptable donors and immunologic rejection of the donated tissue by the recipient remain major hindrances. It is understood that the rejection of a donor's tissue involves both cellular and humoral mechanisms, mediated respectively by T cells and antibodies. The recipient's immune system especially targets histocompatibility antigens on the transplanted cells that are not seen as "self but rather as foreign entities. Except for cases of organ donation between immunologically identical individuals or the special instance of transplantation in individuals with severe combined immunodeficiency disease, the donor's histocompatibility antigens will not completely match the recipient's histocompatibility antigens, and the recipient's immune system will almost certainly react to the incompatible donor's organs, tissues or cells.
[0005] With respect to immunologically-mediated rejection, the most potent of the histocompatibility antigens are the major histocompatibility complex (MHC) antigens known in humans as the human leukocyte antigens (HLAs) which are present on virtually all of the nucleated cells of the human body. The MHC class I antigens include the HLA-A, HLA-B and HLA-C antigens. Since each person receives genes encoding one set of these antigens
from each parent, human cells typically express six of these major HLA class I antigens. Organ donors and recipients can also differ in their MHC class II antigens (HLA class II antigens). In addition to the major histocompatibility antigens, there are several minor histocompatibility antigens and other antigens that may limit transplantation success including the ABO and Rh systems.
[0006] When tissue or cells are transplanted, it is desirable to match, to the maximum extent possible, the histocompatibility antigens of the donor and the recipient. The best
immunologic match between donor and recipient is between identical twins, since they share the same major HLA antigens and the same minor histocompatibility antigens; therefore, the recipient identical twin will immunologically tolerate the identical twin donor's organs, tissue or cells.
[0007] More commonly, however, the donor and recipient are not genetically identical resulting in some degree of rejection to the transplanted tissue. To minimize this rejection and permit survival of the engrafted tissue, efforts are routinely made to find the best match between donor and recipient. Even in the best case scenario, there is still a high probability that the minor histocompatibility antigens differ (and likely the major HLA antigens as well), and the donor and recipient will almost certainly be sufficiently distinct in terms of cellular antigens, which results in some degree of graft rejection. In some circumstances, a negative cross-match indicates a recipient has antibodies against the red blood cells of the donor, in which case the donor cannot donate tissue or cells to the recipient without the recipient's immune system responding. Due partly to these negative cross-matches, only a small percentage of available donor-organs or donor-tissues are actually suitable for any given potential recipient.
[0008] If transplantation is carried out, the adverse reactions following transplantation of an organ or tissue from one genetically distinct individual to another can cause difficulties. For example, immunologic rejection of a transplanted organ or tissue can be particularly dangerous if the organ is life-sustaining, such as a heart, liver or lung. The destruction of such an organ may lead directly to the death of the patient. In other circumstances, the quality of life of the recipient can be adversely affected by rejection of transplanted tissues such as insulin-producing pancreatic islet cells or kidneys.
[0009] In order to prevent or limit the rejection, various agents and therapies have been used including: (1) corticosteroids, such as prednisone; (2) cytotoxic drugs, such as azathioprine
and cyclophosphamide; (3) x-ray irradiation therapy; (4) anti-lymphocyte and anti-thymocyte globulins; (5) cyclosponne; and (6) monoclonal antibodies, such as OKT3, which reacts specifically with the CD3 antigen-recognition structure of human T cells and blocks the T cell effector function involved in allograft rejection. These agents and therapies are all administered post-transplant and introduce their own undesirable side effects. For example, immunosuppressive drugs, such as prednisone and cyclosponne, are globally
immunosuppressive, which greatly increases the susceptibility of the recipient to serious infections and also increases the susceptibility of the recipients to opportunistic infections, against which normal individuals have strong defenses. High doses of corticosteroids may also cause cataracts, precipitate diabetes mellitus and hypertension, and/or cause
demineralization of supporting bones, leading to arthritis or osteoporosis. Cyclosponne may cause hypertension, tremors, anorexia and elevated low-density lipoprotein levels. It also has major toxic effects on the kidney, which may lead to decreased renal function. Cytotoxic agents may cause anemia and thrombocytopenia and sometimes hepatitis. The anti- lymphocyte globulins may cause fever, hypotension, diarrhea, or sterile meningitis. OKT3 may cause chills and fever, nausea, vomiting, dianhea, rash, headache, photophobia and occasional episodes of life- threatening acute pulmonary edema.
[0010] In addition to the issues of transplant rejection, the need for chronic immune suppression following transplantation and the resulting adverse effects of post-transplant treatment, there is a marked shortage of human organ and tissue donors compared to the number of patients requiring a transplant.
[001 1] Xenografts, herein defined as transplants from another species, could potentially resolve the shortage of transplantable organs and tissues. Xenografts have been used in the past for short term life support when a recipient urgently requires a transplant and no suitable donor is available. Such uses, however, have only been temporary measures to provide additional time to locate a suitable human donor. The potential use of xenografts as long-term grafts for human recipients is limited by the same major issues that affect allografts; i.e., rejection of the donor graft and the adverse effects of anti-rejection treatments. The problem of rejection is even heightened with xenografts as the risk of rejection of xenografts is considered to be even greater than for allografts.
[0012] Reducing the risk of rejection of donated tissue, xenograft and/or allograft, especially with few excessive adverse effects is desirable. For example, an immunologically-specific immune system suppressant which has few or no side-effects would be valuable. Previous
methods aimed at modulating a recipient's response to a donor graft have been disclosed. See, for example, US Patent No. 6,060,049, US Patent No. 5,560,91 1, US Patent No.
5,728,812, International Patent Application No. WO 84/02848, US Patent Application No. 2008/0127357 and US Patent Application No. 2001/0053362).
SUMMARY
[0013] In part, the present disclosure describes monoclonal anti-anti-anti-MHC antibodies.
[0014] In part, the present disclosure describes methods of production of anti-anti-anti-MHC antibodies.
[0015] In part, the present disclosure describes uses of monoclonal anti-anti-anti-MHC antibodies.
[0016] In part, the present disclosure describes a use monoclonal anti-anti-anti-MHC antibodies in the treatment of degenerative diseases including autoimmune diseases and cancers.
[0017] In part, the present disclosure describes a use of monoclonal anti-anti-anti-MHC
[0018] In part, the present disclosure describes a use of antibodies in reducing a recipient's immune response to donated tissue. The present use comprises introducing monoclonal anti- anti-anti -(donor MHC) antibodies to the recipient's immune system.
[0019] In part, the present disclosure describes compositions comprising monoclonal anti- anti-anti-MHC antibodies.
[0020] In part, the present disclosure describes rodent monoclonal anti-anti-anti-MHC antibodies.
[0021] In part, the disclosure describes fragments of monoclonal anti-anti-anti-MHC antibodies.
[0022] In part, the present disclosure describes a method of producing rodent monoclonal anti-anti-anti-MHC antibodies.
[0023] In part, the present disclosurer describes a use of monoclonal anti-anti-anti-MHC antibodies to facilitate tissue donation between appropriate pairs of vertebrate organisms. For example, organ donation between spouses, other relatives, partners, or other individuals. Further, the present disclosure describes a means for preparing a vertebrate organism or organisms for possible tissue donation to another vertebrate, for example in situations where
married or common-law spouses wish to donate organs to their spouse, is also desired. Each member of a couple could benefit from being made immunologically tolerant to the tissue of the other. Then each member would be available as an organ donor for the other, should the need arise. This would facilitate the use of living donors for transplantations.
[0024] In part, the present disclosure describes a use of monoclonal anti-anti-anti-MHC antibodies in making each member of a pair of vertebrate organisms ("partners")
immunologically tolerant to the tissue and organs of the other.
[0025] In part, the present disclosure describes a method of supplying monoclonal anti-anti- anti-(donor MHC) antibodies suitable for administration to an organ recipient, the method comprising: a) receiving input parameters, said parameters comprising donor lymphocytes; b) obtaining, based on the input parameters, an appropriate monoclonal anti-anti- anti-(donor MHC) antibodies for facilitating the transplantation of tissue from said donor to a recipient; and c) distributing said monoclonal anti-anti-anti-(donor MHC) antibodies to the
delivery location.
[0026] As used herein, the term "immune response" means the production of antibodies and/or the induction of cell mediated immunity specific for an antigen, including especially the production of antibodies or the induction of cell mediated immunity specific for transplantation antigens.
[0027] As used herein, the term "facilitating transplantation" means reducing the risk of rejection of donated tissue by a recipient. For example, when the donated tissue is an organ the term will refer to reducing the chance of rejection of the organ by the recipient and a consequent improvement in the chances of the transplantation being successful. The facilitation can include inducing transplantation tolerance by the administration of monoclonal anti-anti-anti-(donor MHC) antibodies in non-immunogenic form to a prospective donor recipient. This may be together with the application of a prospective donor skin graft. This process can induce transplantation tolerance in the recipient with respect to donor tissue such as donor organs, and organ transplantation can be attempted as needed.
[0028] As used herein, the term "idiotype" means the unique set of antigenic determinants (or epitopes) of the V region of an antibody, lymphocyte receptor or specific T cell factor, wherein such idiotype can potentially induce the formation of anti-idiotypic antibodies.
[0029] As used herein, the term "anti-idiotype" means the V region of an antibody, lymphocyte receptor or specific T cell factor that is complementary to the V region of the respective idiotype.
[0030] As used herein, the term "anti-anti-self antibody" in an alloimmune serum is an antibody that binds to an idiotype in the converse alloimmune serum (see Figure 1). In the case of complementary alloimmune sera, as shown for example in Figure 1 , anti-anti-P antibodies in a P anti-Q serum bind specifically to anti-P and anti-anti-anti-P antibodies in a Q anti-P serum. Anti-anti-self antibodies, for example anti-anti-P in Figure 1, are
predominantly anti-anti-(self MHC), because of the strong role that MHC antigens play in alloimmunity, but other self antigens also play a role in the selction of anti-anti-self antibodies, including minor histocompatibility antigens.
[0031] As used herein, the term "anti-anti-anti-MHC antibody" in the context of a P anti-Q immune response, where P and Q are vertebrates, means an antibody present in a P anti-Q serum, or a monoclonal antibody, that binds to the V regions of the anti-anti-Q antibodies present in a Q anti-P serum, but does not substantially bind to vertebrate Q MHC antigens (see Figure 1). In Figure 1 anti-anti-anti-Q antibodies may be anti-anti-anti-(Q MHC).
Hybridomas that produce monoclonal anti-anti-anti-donor antibodies can be selected using alloimmune animals on the basis of their V regions having complementarity to anti-anti- donor antibodies without substantially binding to donor MHC antigens. These anti-anti-anti- MHC antibodies are believed to bind in ELISA assays to HIV antigens, and it is believed that hybridomas that make monoclonal anti-anti-anti-MHC antibodies can be selected using alloimmune animals and selecting hybridomas with V regions that bind to HIV antigens.
[0032] As used herein, an animal P that has made an anti-Q immune response, where P and Q are vertebrates, is "conversely alloimmune" to an animal Q that has made an anti-P immune response.
[0033] As used herein, the term "converse alloimmune serum" for a P anti-Q serum is a Q anti-P antiserum.
[0034] As used herein, the term "monoclonal anti-anti-anti-graft antibody" is synonymous with "monoclonal anti-anti-anti-(donor MHC) antibody".
[0035] As used herein, "HIV" is the human immunodeficiency virus, including especially the HIV-1 human immunodeficiency virus.
[0036] As used herein, the term "monoclonal donor-specific anti-HIV antibodies" means monoclonal antibodies that are obtained by immunizing a vertebrate with donor lymphocytes and selecting hybridomas with V regions that bind to HIV antigens.
[0037] As used herein, "non-immunogenic" means delivery in a manner that does not induce significant production of antibodies that bind to the monoclonal anti-anti-anti-MHC antibodies being administered. For example, the delievery may be without an adjuvant, via a non-immunogenic route, and/or in non-immunogenic amounts.
[0038] As used herein, the term "anti-anti-(donor MHC) antibody" means an anti-idiotype antibody that is present in an alloimmune serum and that is directed against the idiotypes of anti-(donor MHC) antibodies and anti-(donor MHC) T cell receptors that are present in the converse antiserum, and can recognize and interact with anti-(donor MHC) antibodies and anti-(donor MHC) T cell receptors that are present in the converse antiserum.
[0039] As used herein, the term "recipient" refers to a vertebrate organism which receives transplanted tissue from a genetically distinct organism.
[0040] As used herein, the term "donor" refers to a vertebrate organism from which tissue is removed or otherwise derived by, for example, tissue culturing techniques, and introduced into the recipient organism. The donor may be of the same (allograft) or different (xenograft) species.
[0041] As used herein, the term "catalyst animal" refers to a vertebrate organism that provides tissue, preferably lymphocytes, that is used for the immunization of a potential organ donor vertebrate, such that the donor makes an immune response that includes the production of anti-anti-donor antibodies.
[0042] As used herein, the term "tissue" means one or more nucleated cells. Frequently, the tissue will be from an organ such as, for example, skin, heart, lung, kidney, liver, spleen, thymus, lymph node, blood, bone marrow, pancreas, intestine, gall bladder, prostate, ovary, muscle, limbs, or the like. The tissue may be a whole or partial organ.
[0043] This summary does not necessarily describe the entire scope of the present invention. Other aspects, features and advantages of the invention will be apparent to those of ordinary skill in the art upon review of the following description of specific embodiments of the invention.
BRIEF DESCRIPTION OF THE DRAWINGS
[0044] Figure 1 shows a system by which anti-, anti-anti-, and anti-anti-anti- antibodies are defined and are believed to be present as polyclonal antibodies in alloimmune or
xenoimmune vertebrates. A vertebrate "P" with MHC antigens P that is alloimmune or made alloimmune to a vertebrate "Q" with MHC antigens Q is believed to make anti-Q, anti-anti-P and anti-anti-anti-Q antibodies. If the vertebrate "Q" is alloimmune or is made alloimmune to the vertebrate "P", "Q" is believed to make anti-P, anti-anti-Q and anti-anti-anti-P antibodies. The anti-anti-Q antibodies in the Q anti-P serum are believed to have specificity for anti-Q and anti-anti-anti-Q polyclonal antibodies in the P anti-Q serum. The monoclonal anti-anti- anti-MHC antibodies of this invention are believed to have specificity for anti-anti-MHC antibodies without binding to MHC antigens, as shown here.
[0045] Figure 2 illustrates the IJ phenomenon in the context of the symmetrical immune network theory.
[0046] Figure 3 shows a possible mechanism for an anti-anti-(MHC class II) monoclonal antibody in immunogenic form being a vaccine for the prevention of infection with HIV.
[0047] Figure 4 shows a possible mechanism for the induction of transplantation tolerance using anti-anti-(graft MHC) antibodies.
[0048] Figure 5 shows a method for the induction of transplantation tolerance between two vertebrates P and Q using the immune system of a third party "catalyst" vertebrate C in the production of anti-anti-self polyclonal antibodies.
[0049] Figure 6 shows a method for obtaining monoclonal anti-anti-anti-MHC antibodies and their use in a transplantation technology.
[0050] Figure 7 shows a possible mechanism by which anti-anti-anti-(graft MHC) antibodies mediate transplantation tolerance.
[0051] Figure 8 shows a possible mechanism for the stabilization of an immune system by monoclonal anti-anti-(self MHC) antibodies.
[0052] Figure 9 shows a possible mechanism for the stabilization of an immune system by monoclonal anti-anti-anti-MHC antibodies.
DETAILED DESCRIPTION
[0053] In part, the present disclosure describes monoclonal anti-anti-anti-MHC antibodies and uses thereof. The present disclosure furthermore describes methods for the production of monoclonal anti-anti-anti-MHC antibodies and uses of monoclonal anti-anti-anti-MHC antibodies such as the treatment of degenerative disorders including autoimmune diseases and cancers. In the case of autoimmunity the immune system may be considered too active, and cancers may proliferate when the immune system is not active enough.
[0054] In part, the present disclosure describes a method of reducing the risk of the rejection of tissue transplanted into a recipient animal from a donor animal. In an embodiment, the present disclosure provides a method of producing anti-idiotypic antibodies against antigen receptors on the surface of a recipient's lymphocytes and the use of such anti-idiotypic antibodies in preventing transplant rejection by a recipient by inducing a state of the recipient's immune system that is suppressed with regard to responding immunologically against the transplanted organ. The present disclosure further relates to compositions, uses, kits, and the like.
[0055] As shown in Figure 1, the serum of an animal P that has been immunized with Q lymphocytes contains anti-Q, anti-anti-P, and anti-anti-anti-Q antibodies, while the serum of an animal Q that has been immunized with lymphocytes of an animal P contains anti-P, anti- anti-Q, and anti-anti-anti-P antibodies. In the context of the symmetrical immune network theory, the anti-anti-anti-P antibodies and anti-anti-anti-Q antibodies are called anti-IJp and anti-IJQ antibodies in mice. The diagonal lines in this diagram indicate that all of the specific antibodies induced in the P anti-Q serum have complementarity to antibodies in the Q anti-P serum. Hence as used herein, the term "anti-anti-anti-MHC antibody" in the context of an P anti-Q immune response, where P and Q are vertebrates, means an anti-anti-anti-(Q MHC) antibody, or a monoclonal antibody, that binds to the V regions of anti-anti-(Q MHC) antibodies present in a Q anti-P serum, but not to vertebrate Q MHC antigens.
[0056] As used herein, the term "co-selection" means the mutual positive selection of individual members from within two diverse populations, such that selection of members within each population is dependent on interaction with (recognition of) one or more members within the other population. Figure 2 shows how helper T cells and suppressor T
cells are co-selected and can give rise to IJ determinants that are expressed on suppressor T cells. See Hoffinann, G. W. 1994. Immunol. Cell Biol, 72:338.
[0057] Figure 3 shows how monoclonal anti-anti-MHC antibodies in immunogenic form may induce an anti-anti-anti-MHC immune response that is also an anti-HIV immune response, and hence monoclonal anti-anti-MHC antibodies may function as a vaccine for protection against HIV infection. While not wishing to be bound by theory it is believed that HIV preferentially infects HIV-specific helper T cells (Hoffmann, G. W. 1994. Immunol. Cell Biol, 72:338-346; Douek D.K., et al. 2002. Nature, 417: 95-98), thus HIV could be selected to be similar to anti-anti-MHC antibodies.
[0058] Immunization with protein antigens in immunogenic form can result in the production of antibodies that are both specific for the antigen and antiidiotypic. Hsu et al. (1989) Int. Immunol. 1, 197-204; Forsyth et al. (1990) J. Immunol. 145, 215-223. This dual specificity could mean an anti-anti-anti-MHC antibody may induce an anti-HIV immune response, and hence may also be effective as a vaccine in protection against HIV.
[0059] While not wishing to be bound by theory, the present method is believed to work based on the symmetrical immune network theory, according to which the variable regions (the "V regions") of antibodies, specific T cell factors, and specific lymphocyte receptors recognize each other, and according to which such recognition is a key element in the regulation of the immune system. The V regions of antibodies, lymphocyte receptors and specific T cell factors each have a set of antigenic determinants (or epitopes) that characterize each type of antibody, receptor and specific T cell factor. These sets of antigenic
determinants are referred to as idiotypes and function in their own right as antigenic stimuli, which can induce the formation of anti-idiotypic antibodies. An anti-idiotype is a set of antigenic determinants complementary to its respective idiotypes. The interactions between idiotypes and anti-idiotypes and the interaction between idiotypic receptors and anti-idiotypic receptors is thought to be a major factor in regulating a specific immune response (see, for example, Wigzell, H. and Binz, H. 1980. Progress in Immunology IV, eds. Fougereau, M. and Dausset, J. Academic Press, N.Y., p. 94-103; Infante, et al. 1982. J. Exp. Med. 155: 1100; Bona, C. and Paul, E. 1980. Regulatory T Lymphocytes, eds., Pernis, B. and Vogel, H.J. Academic Press, N.Y., p. 292). The interactions between idiotypes and anti-idiotypes is thought to be symmetrical. The symmetrical interactions are thought to include symmetrical stimulation, inhibition, and elimination interactions. The symmetrical immune network
theory is described in "Immune Network Theory" by Hoffmann, G. W., published at online at www.networkimmunologyinc.com. However, for a variety of reasons symmetrical immune network theory has been largely discounted by the scientific community and the vast majority of immunologists are not further pursuing or researching the theory. One issue with the theory is that it is based on the presumed existence of molecules called specific T cell factors, or "tabs", which are integral to the symmetrical immune network theory, but are not part of the reigning paradigm of adaptive immunity in the year 2010. A second cause for the unpopularity of the symmetrical immune network theory is known as the IJ paradox. Tabs were shown experimentally to express IJ determinants, and IJ was clearly mapped in mice to within the MHC, but no gene for IJ could be found there. This was the IJ paradox. The IJ paradox led to the widespread conclusions that "IJ does not exist" and "suppressor tabs do not exist". Since tabs are important in the symmetrical immune network theory, it has been widely concluded that the symmetrical immune network theory is wrong.
[0060] In spite of the technical prejudice that exists against immune network theory , the present disclosure describes anti-anti-anti-MHC antibodies and uses thereof.
[0061] In part, the present disclosure comprises obtaining monoclonal anti-anti-anti-MHC and/or fragments of monoclonal anti-anti-anti-MHC antibodies. These antibodies may be produced in any suitable method such methods being well known in the art. Preferred methods of producing monoclonal anti-anti-anti-MHC mAbs are described below in
Examples 1 and 2.
[0062] In part, the present use of monoclonal anti-anti-anti-MHC antibodies comprises administering the antibodies to the recipient in non-immunogenic form. The dose of monoclonal anti-anti-anti-MHC antibodies is determined by one skilled in the art. Preferably, the recipient is given monoclonal anti-anti-anti-(donor MHC) antibodies intravenously or intra-peritoneal without an adjuvant, in amounts preferably between about 10 ng and about 10 μg of anti-anti-(donor MHC) antibody per kilogram weight of the recipient per dose, even more preferably about 1 μ of anti-anti-(donor MHC) antibody per kilogram of the recipient per dose.
[0063] In an embodiment, donor serum comprising anti-anti-(donor MHC) antibodies is administered to the recipient, which administration comprises: (i) obtaining serum or purified IgG antibodies from an immunized donor; (ii) adsorbing the donor's serum or purified IgG antibodies using recipient tissue in order to remove any anti-(recipient MHC) antibodies; and
(iii) administering the resulting serum or purified IgG antibodies containing anti-anti-(donor MHC) activity to the recipient to facilitate acceptance of the donor's graft.
[0064] Figure 4 shows how a possible mechanism for how anti-anti-graft antibodies, which are also known as anti-anti-(donor MHC) antibodies, are believed to facilitate the induction of transplantation tolerance. The anti-anti-graft antibodies, when administered to the recipient, stimulate T cells of the recipient. The anti-anti-graft antibodies stimulate anti-anti- anti-graft T cells and anti-graft T cells, which causes the secretion of specific T cell factors. These T cell factors are protein molecules that are postulated to be monovalent (i.e., having only one V region). The V regions of specific T cell factors mediate the T cell factors' specificity. Since T cell factors are monovalent, T cell factors in soluble form cannot crosslink complementary receptors; however, such soluble T cell factors can be stimulatory when presented on the surface of non-specific accessory cells ("A cells") including macrophages.
[0065] The T cell factors that are secreted by the anti-anti-anti-graft T cells and anti-graft T cells have anti-anti-anti-graft specificity and anti-graft specificity. These T cell factors of a given specificity are adsorbed by and presented on the surface of macrophages. The surface of the macrophage is a highly immunogenic surface, and the presence of the specific T cell factors on the surface of macrophages stimulate T cells bearing receptors that are
complementary to the T cell factors on the macrophage surface. While not wishing to be bound by theory, it is believed that the anti-anti-anti-graft T cell factors and anti-graft T cell factors specifically stimulate anti-anti-graft T cells. These anti-anti-graft T cells secrete anti- anti-graft specific T cell factors, which in turn are presented on the surface of macrophages, resulting in the proliferation of anti-graft T cells and anti-anti-anti-graft T cells. As a result of the symmetric stimulation of T cells, the macrophages of the recipient become armed with a mixture of anti-graft, anti-anti- graft and anti-anti-anti-graft T cell factors. Consequently, the immune system of the recipient goes into a state in which there are elevated levels of anti- graft, anti-anti-graft and anti-anti-anti-graft T cells, and their mutual stimulation leads to a significant level of these cells and their corresponding antigen-specific T cell factors. In the context of the symmetrical immune network theory, this is thought to be a specifically suppressed state for the recipient especially with regard to the MHC antigens of the organ donor. The recipient's immune system is therefore selectively suppressed with respect to any immunity against the antigens of the donor, while still leaving the remainder of the immune system intact and not injuring other important organs, tissues or cells.
[0066] The present disclosure may involve a donor animal that is a different species from the recipient animal, i.e., a xenogeneic transplantation. Many species could potentially be used as donor animals and different animals offer advantages for select uses. Preferably, donor animals are of the class Mammalia. Of the class Mammalia, five orders are particularly suitable for human recipients: primates, artiodactyls, carnivores, rodents, and lagamorphs.
[0067] In an embodiment a potential transplant recipient receives either anti-anti-donor antibodies or monoclonal anti-anti-anti-donor antibodies. The antibodies may be given substantially simultaneously with the transplant. An additional dose or doses may be delivered at intervals thereafter. The antibodies may also be given prior to the transplant. In a variation, the antibodies are given substantially simultaneously with a skin graft, and optionally at intervals thereafter. The anti-anti-donor or monoclonal anti-anti-anti-donor antibodies may also be given prior to the time of a skin graft. When the skin graft is stably accepted, the potential transplant recipient is transplantation tolerant with respect to the tissue of the potential donor, and can receive a transplant as needed.
[0068] An embodiment of the present method involves immunizing a prospective organ donor A with tissue of a prospective transplant recipient B, preferably including lymphocytes. The prospective donor A is immunized with tissue of the organ recipient B. The tissue of the recipient used for the immunization is preferably lymphocytes. For safety, the tissue of the recipient used for immunization can be gamma irradiated, for example with 3000 rads of gamma irradiation. Polyclonal IgG obtained from the immunized donor can be absorbed using B tissue, for example B lymphocytes, removing the anti-B and anti-anti-anti-B antibodies, and leaving serum or IgG containing anti-anti-A antibodies. These polyclonal antibodies can be given to the potential organ recipient in non-immunogenic form preferably starting at the time point of a skin graft from the potential organ donor. Administration of the anti-anti-A antibodies may also be given prior to the time of skin tissue transplantation. The number of administrations that are needed may vary depending on circumstances but, for example, there may be two or more, three or more, four or more, ten or more, or twenty or more administrations of anti-anti-A antibodies. The administrations may be at any suitable time interval. For example, the time between administrations may be initially relatively short, e.g. one or two days, then after a week or so the time intervals can be extended, e.g. doubled, and then systematically increased as needed. The dose in each given case can be varied depending on the response of the recipient. For example any inflammation at the site of the skin graft is indicative of the need for more doses of anti-anti-A antibodies or of larger doses
of the anti-anti-A antibodies. Following stable acceptance of the skin graft, the prospective organ recipient B is able to accept an organ transplant from the ogan donor A at any time that this is needed. This method allows for the induction of one way transplantation tolerance, since the donor A becomes immune to the tissue of the recipient B and cannot also be made transplantation tolerant with respect to tissue of the recipient.
[0069] An embodiment of the present method involves the induction of reciprocal transplantation tolerance between two vertebrates, for example between two members of a couple A and B. This embodiment allows for both A and B to become potential organ donors for each other if and when the need should arise. This embodiment involves a third party catalyst vertebrate C as shown in Figure 5. Both A and B are immunized with tissue of C, preferably including lymphocytes. A makes anti-C, anti-anti-A and anti-anti-anti-C antibodies, while B makes anti-C, anti-anti-B and anti-anti-anti-C antibodies. The A and B immune sera are absorbed using C tissue to remove anti-C and anti-anti-anti-C antobodies, leaving anti-anti-A and anti-anti-B serum respectively. The anti-anti-A antibodies are administered in non-immunogenic form to B at the time of the application of a B skin graft and at intervals following the application of the skin graft. Similarly, the anti-anti-B antibodies are administered in non-immunogenic form to A at the time of the application of a B skin graft and at intervals following the application of the skin graft. Following stable acceptance of the skin grafts, A and B are mutually transplantation tolerant with respect to the other, and each can receive an organ transplant from the other if and when needed. The skin grafts are stably accepted when there is no evidence of rejection within a suitable period, for example when the skin grafts have not been rejected and there is no inflammation at the site of the skin graft three months after the application of the skin graft.
[0070] Figure 6 shows a method for obtaining monoclonal anti-anti-anti-MHC antibodies and their use in a transplantation technology. A vertebrate CI is immunized with lymphocytes of a vertebrate P and a vertebrate C2 is immunized with lymphocytes of a vertebrate Q. The B lymphocytes of vertebrate CI are used to make hybridomas. Hybridomas are selected that have V regions that bind to HIV antigens. These hybridomas make monoclonal HIV-specific anti-anti-anti-(P MHC) antibodies. The B lymphocytes of vertebrate C2 are used to make hybridomas. Hybridomas are selected that have V regions that bind to HIV antigens. These hybridomas make monoclonal HIV-specific anti-anti-anti-(Q MHC) antibodies. P receives a Q skin graft together with anti-anti-anti-Q antibodies and Q receives a P skin graft together
with anti-anti-anti-P antibodies. When the skin grafts are stably accepted, P and Q are each ready to receive a transplant from the other, should the need arise.
[0071] Figure 7 shows a possible mechanism by which monoclonal anti-anti-anti-graft MHC antibodies mediate transplantation tolerance. Alpha (a) is an abbreviation for "anti-" and "tab" means specific T cell factor. Small doses of the anti-anti-anti-graft antibodies in non- immunogenic form stimulate anti-anti-graft T cells that secrete anti-anti-graft specific T cell factors (tabs). These specific T cell factors bind to the surface of non-specific accessory cells including macrophages (A cells), where they present an array that is stimulatory for anti-graft T cells and anti-anti-anti-graft T cells that secrete anti-graft tabs and anti-anti-anti-graft tabs respectively. The A cells thus become armed with a mixture of anti-graft, anti-anti-graft and anti-anti-anti-graft tabs, and the immune system is stimulated to go to a state with elevated levels of anti-graft, anti-anti-graft and anti-anti-anti-graft T cells, which in the context of the symmetrical immune network theory is believed to be a specifically suppressed state with regard to making an immune response to the graft.
[0072] Figure 8 shows a possible mechanism for the stabilization of an immune system by monoclonal anti-anti-(self MHC) antibodies. Such stabilization is for the prevention and treatment of degenerative diseases including autoimmunity and cancers. The Greek letter alpha (a) is an abbreviation for "anti-" and "tab" means specific T cell factor. Anti-anti-(self MHC) antibodies (aaself) stimulate aself and aaaself T cells. The aself T cells are also stimulated by the self. The aself and aaaself T cells secrete aself and aaaself tabs respectively. The aself and aaaself tabs bind to the surface of A cells. The a(self MHC) and aaaself tabs on the A cells stimulate aaself T cells. The aaself T cells secrete aaself tabs that also bind to the surface of A cells. Thus the A cells become armed with a mixture of aself, aaself and aaaself tabs. The armed A cell stimulates the proliferation of aself, aaself and aaaself T cells. The resulting state of the system with elevated levels of aself, aaself and aaaself T cells is stabilized and is believed to be resistant against making immune responses against self, without being compromised regarding making immune responses to substances that cause a disease or disorder such as cancer cells.
[0073] Figure 9 shows a possible mechanism for the stabilization of an immune system by monoclonal anti-anti-anti-MHC antibodies. Such stabilization is for the prevention and treatment of degenerative diseases including autoimmunity and cancers. Alpha (a) is an abbreviation for "anti-" and "tab" means specific T cell factor. Small doses of the anti-anti- anti-(self MHC) antibodies in non-immunogenic form stimulate anti-anti-self T cells that
secrete anti-anti-self specific T cell factors (tabs). These specific T cell factors bind to the surface of non-specific accessory cells including macrophages (A cells), where they present an array that is stimulatory for anti-self T cells and anti-anti-anti-self T cells that in turn secrete anti-self tabs and anti-anti-anti-self tabs respectively. The A cells thus become armed with a mixture of anti-self, anti-anti-self and anti-anti-anti-self tabs, and the immune system goes to a specifically stabilized state with regard to making immune responses against self, on account of an increase in the level of the centrally important anti-anti-self T cells, without being compromised regarding making immune responses to substances that cause a disease or disorder such as cancer cells.
[0074] The monoclonal anti-anti-anti-MHC antibodies described herein can be used to prevent and/or treat degenerative disorders for example autoimmune disorders and cancers.
[0075] Any suitable autoimmune disorder may be prevented, treated, or the prevention or treatment of the disorder may be aided with the present monoclonal anti-anti-anti-MHC antibodies. Examples of identified autoimmune disorders include, but are not limited to, Achlorhydra; Autoimmune Active Chronic Hepatitis; Acute Disseminated
Encephalomyelitis; Acute hemorrhagic leukoencephalitis; Addison's Disease;
Agammaglobulinemia; Alopecia areata; Amyotrophic Lateral Sclerosis; Ankylosing
Spondylitis; Anti-GBM/TBM Nephritis; Antiphospholipid syndrome; Antisynthetase syndrome; Arthritis; Atopic allergy; Atopic Dermatitis; Autoimmune Aplastic Anemia;
Autoimmune cardiomyopathy; Autoimmune hemolytic anemia; Autoimmune hepatitis;
Autoimmune inner ear disease; Autoimmune lymphoproliferative syndrome; Autoimmune peripheral neuropathy; Autoimmune pancreatitis; Autoimmune polyendocrine syndrome Types I, II, & III; Autoimmune progesterone dermatitis; Autoimmune thrombocytopenic purpura; Autoimmune uveitis; Balo disease/Balo concentric sclerosis; Bechets Syndrome; Berger's disease; Bickerstaff s encephalitis; Blau syndrome; Bullous Pemphigoid;
Castleman's disease; Chagas disease; Chronic Fatigue Immune Dysfunction Syndrome;
Chronic inflammatory demyelinating polyneuropathy; Chronic recurrent multifocal ostomyelitis; Chronic lyme disease; Chronic obstructive pulmonary disease; Churg-Strauss syndrome; Cicatricial Pemphigoid; Coeliac Disease; Cogan syndrome; Cold agglutinin disease; Complement component 2 deficiency; Cranial arteritis; CREST syndrome; Crohns Disease; Cushing's Syndrome; Cutaneous leukocytoclastic angiitis; Dego's disease; Dercum's disease; Dermatitis herpetiformis; Dermatomyositis; Diabetes mellitus type 1 ; Diffuse cutaneous systemic sclerosis; Dressler's syndrome; Discoid lupus erythematosus; Eczema;
Endometriosis; Enthesitis-related arthritis; Eosinophilic fasciitis; Epidermolysis bullosa acquisita; Erythema nodosum; Essential mixed cryoglobulinemia; Evan's syndrome;
Fibrodysplasia ossificans progressiva; Fibromyalgia; Fibromyositis; Fibrosing aveolitis;
Gastritis; Gastrointestinal pemphigoid; Giant cell arteritis; Glomerulonephritis; Goodpasture's syndrome; Graves' disease; Guillain-Barre syndrome (GBS); Hashimoto's encephalitis;
Hashimoto's thyroiditis; Haemolytic anaemia; Henoch-Schonlein purpura; Herpes gestationis; Hidradenitis suppurativa; Hughes syndrome (Antiphospholipid syndrome);
Hypogammaglobulinemia; Idiopathic Inflammatory Demyelinating Diseases; Idiopathic pulmonary fibrosis; Idiopathic thrombocytopenic purpura (Autoimmune thrombocytopenic purpura); IgA nephropathy (Berger's disease); Inclusion body myositis; Inflammatory demyelinating polyneuopathy; Interstitial cystitis; Irritable Bowel Syndrome (IBS); Juvenile idiopathic arthritis; Juvenile rheumatoid arthritis; Kawasaki's Disease; Lambert-Eaton myasthenic syndrome; Leukocytoclastic vasculitis; Lichen planus; Lichen sclerosus; Linear IgA disease (LAD); Lou Gehrig's Disease (Amyotrophic lateral sclerosis); Lupoid hepatitis; Lupus erythematosus; Majeed syndrome; Meniere's disease; Microscopic polyangiitis;
Miller-Fisher syndrome; Mixed Connective Tissue Disease; Morphea; Mucha-Habermann disease; Muckle- Wells syndrome; Multiple Myeloma; Multiple Sclerosis; Myasthenia gravis; Myositis; Narcolepsy; Neuromyelitis optica (Devic's Disease); Neuromyotonia; Occular cicatricial pemphigoid; Opsoclonus myoclonus syndrome; Ord thyroiditis; Palindromic rheumatism; PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus); Paraneoplastic cerebellar degeneration; Paroxysmal nocturnal
hemoglobinuria (PNH); Parry Romberg syndrome; Parsonnage- Turner syndrome; Pars planitis; Pemphigus; Pemphigus vulgaris; Pernicious anaemia; Perivenous encephalomyelitis; POEMS syndrome; Polyarteritis nodosa; Polymyalgia rheumatica; Polymyositis; Primary biliary cirrhosis; Primary sclerosing cholangitis; Progressive inflammatory neuropathy;
Psoriasis; Psoriatic Arthritis; Pyoderma gangrenosum; Pure red cell aplasia; Rasmussen's encephalitis; Raynaud phenomenon; Relapsing polychondritis; Reiter's syndrome; Restless leg syndrome; Retroperitoneal fibrosis; Rheumatoid arthritis; Rheumatoid fever; Sarcoidosis; Schizophrenia; Schmidt syndrome; Schnitzler syndrome; Scleritis; Scleroderma; Sjogren's syndrome; Spondyloarthropathy; Sticky blood syndrome; Still's Disease; Stiff person syndrome; Subacute bacterial endocarditis (SBE); Susac's syndrome; Sweet syndrome;
Sydenham Chorea; Sympathetic ophthalmia; Takayasu's arteritis; Temporal arteritis (Giant cell arteritis); Tolosa-Hunt syndrome; Transverse Myelitis; Ulcerative Colitis;
Undifferentiated connective tissue disease; Undifferentiated spondyloarthropathy; Vasculitis; Vitiligo; Wegener's granulomatosis; Wilson's syndrome; Wiskott-Aldrich syndrome.
[0076] Any suitable cancer may be prevented, treated, or the prevention or treatment of the cancer may be aided with the present monoclonal anti-anti-anti-MHC antibodies. Examples of identified or suspected cancers include, but are not limited to, Acute lymphoblastic leukemia; Acute myeloid leukemia; Adrenocortical carcinoma; AIDS-related cancers; AIDS- related lymphoma; Anal cancer; Appendix cancer; Astrocytoma, childhood cerebellar or cerebral; Basal cell carcinoma; Bile duct cancer, extrahepatic; Bladder cancer; Bone cancer, Osteosarcoma/Malignant fibrous histiocytoma; Brainstem glioma; Brain tumor; Brain tumor, cerebellar astrocytoma; Brain tumor, cerebral astrocytoma/malignant glioma; Brain tumor, ependymoma; Brain tumor, medulloblastoma; Brain tumor, supratentorial primitive neuroectodermal tumors; Brain tumor, visual pathway and hypothalamic glioma; Breast cancer; Bronchial adenomas/carcinoids; Burkitt lymphoma; Carcinoid tumor, childhood; Carcinoid tumor, gastrointestinal; Carcinoma of unknown primary; Central nervous system lymphoma, primary; Cerebellar astrocytoma, childhood; Cerebral astrocytoma/Malignant glioma, childhood; Cervical cancer; Childhood cancers; Chronic lymphocytic leukemia; Chronic myelogenous leukemia; Chronic myeloproliferative disorders; Colon Cancer;
Cutaneous T-cell lymphoma; Desmoplastic small round cell tumor; Endometrial cancer; Ependymoma; Esophageal cancer; Ewing's sarcoma in the Ewing family of tumors;
Extracranial germ cell tumor, Childhood; Extragonadal Germ cell tumor; Extrahepatic bile duct cancer; Eye Cancer, Intraocular melanoma; Eye Cancer, Retinoblastoma; Gallbladder cancer; Gastric (Stomach) Cancer; Gastric (Stomach) Cancer, Childhood; Gastrointestinal Carcinoid Tumor; Gastrointestinal Stromal Tumor (GIST); Germ Cell Tumor, Extracranial, Childhood; Germ Cell Tumor, Extragonadal; Germ Cell Tumor, Ovarian; Gestational Trophoblastic Tumor; Glioma, Adult; Glioma, Childhood Brain Stem; Glioma, Childhood Cerebral Astrocytoma; Glioma, Childhood Visual Pathway and Hypothalamic; Gastric Carcinoid; Hairy cell leukemia; Head and neck cancer; Heart cancer; Hepatocellular (liver) cancer; Hodgkin lymphoma; Hypopharyngeal cancer; Hypothalamic and visual pathway glioma, childhood; Intraocular Melanoma; Islet Cell Carcinoma (Endocrine Pancreas);
Kaposi sarcoma; Kidney cancer (renal cell cancer); Laryngeal Cancer; Leukemias; Leukemia, acute lymphoblastic (also called acute lymphocytic leukemia); Leukemia, acute myeloid (also called acute myelogenous leukemia); Leukemia, chronic lymphocytic (also called chronic lymphocytic leukemia); Leukemia, chronic myelogenous (also called chronic myeloid
leukemia); Leukemia, hairy cell; Lip and Oral Cavity Cancer; Liver Cancer (Primary); Lung Cancer, Non-Small Cell; Lung Cancer, Small Cell; Lymphomas; Lymphoma, AIDS-related; Lymphoma, Burkitt; Lymphoma, cutaneous T-Cell; Lymphoma, Hodgkin; Lymphomas, Non-Hodgkin (an old classification of all lymphomas except Hodgkin's); Lymphoma, Primary Central Nervous System; Macroglobulinemia, Waldenstrom; Malignant Fibrous Histiocytoma of Bone/Osteosarcoma; Medulloblastoma, Childhood; Melanoma; Melanoma, Intraocular (Eye); Merkel Cell Carcinoma; Mesothelioma, Adult Malignant; Mesothelioma, Childhood; Metastatic Squamous Neck Cancer with Occult Primary; Mouth Cancer; Multiple Endocrine Neoplasia Syndrome, Childhood; Multiple Myeloma/Plasma Cell Neoplasm; Mycosis Fungoides; Myelodysplasia Syndromes; Myelodysplastic/Myeloproliferative Diseases; Myelogenous Leukemia, Chronic; Myeloid Leukemia, Adult Acute; Myeloid Leukemia, Childhood Acute; Myeloma, Multiple (Cancer of the Bone-Marrow);
Myeloproliferative Disorders, Chronic; Nasal cavity and paranasal sinus cancer;
Nasopharyngeal carcinoma; Neuroblastoma; Non-Hodgkin lymphoma; Non-small cell lung cancer; Oral Cancer; Oropharyngeal cancer; Osteosarcoma/malignant fibrous histiocytoma of bone; Ovarian cancer; Ovarian epithelial cancer (Surface epithelial-stromal tumor); Ovarian germ cell tumor; Ovarian low malignant potential tumor; Pancreatic cancer; Pancreatic cancer, islet cell; Paranasal sinus and nasal cavity cancer; Parathyroid cancer; Penile cancer; Pharyngeal cancer; Pheochromocytoma; Pineal astrocytoma; Pineal germinoma;
Pineoblastoma and supratentorial primitive neuroectodermal tumors, childhood; Pituitary adenoma; Plasma cell neoplasia/Multiple myeloma; Pleuropulmonary blastoma; Primary central nervous system lymphoma; Prostate cancer; Rectal cancer; Renal cell carcinoma (kidney cancer); Renal pelvis and ureter, transitional cell cancer; Retinoblastoma;
Rhabdomyosarcoma, childhood; Salivary gland cancer; Sarcoma, Ewing family of tumors; Sarcoma, Kaposi; Sarcoma, soft tissue; Sarcoma, uterine; Sezary syndrome; Skin cancer (nonmelanoma); Skin cancer (melanoma); Skin carcinoma, Merkel cell; Small cell lung cancer; Small intestine cancer; Soft tissue sarcoma; Squamous cell carcinoma
(nonmelanoma); Squamous neck cancer with occult primary, metastatic; Stomach cancer; Supratentorial primitive neuroectodermal tumor, childhood; T-Cell lymphoma, cutaneous (Mycosis Fungoides and Sezary syndrome); Testicular cancer; Throat cancer; Thymoma, childhood; Thymoma and Thymic carcinoma; Thyroid cancer; Thyroid cancer, childhood; Transitional cell cancer of the renal pelvis and ureter; Trophoblastic tumor, gestational;
Unknown primary site, carcinoma of, adult; Unknown primary site, cancer of, childhood; Ureter and renal pelvis, transitional cell cancer; Urethral cancer; Uterine cancer, endometrial;
Uterine sarcoma; Vaginal cancer; Visual pathway and hypothalamic glioma, childhood;
Vulvar cancer; Waldenstrom macroglobulinemia; and Wilms tumor (kidney cancer), childhood.
[0077] The present anti-anti-anti-MHC antibodies may aid in the treatment, prevention, and/or cure of other degenerative diseases or conditions. Such antibodies may act as immune system stabilizers. Examples of other degenerative diseases or conditions include, but are not limited to, acne, adenoid problems, AIDS, allergies, Alzheimer's disease, asthma,
atherosclerosis, blisters, bronchitis, bunions, burns, canker sores, cataracts, celiac disease, cervical problems, cholesterol problems, chronic fatigue syndrome, chronic pain, circulatory problems, cirrhosis, cold sores, colitis, dermatitis, diverticulitis, eczema, emphysema, endometriosis, epilepsy, fever, gastritis, goiter, gout, hay fever, heart disease, haemorrhoids, hepatitis, hives, inflammation, itching skin, kidney disease, lactose intolerance, Meniere's disease, neuralgia, Parkinson's disease, pelvic inflammatory disease, phlebitis, pleurisy, pregnancy problems, premenstrual syndrome, prostate problems, rashes, sinusitis, tendonitis, thyroid problems, uterine problems, vaginal problems, varicose veins, and warts.
[0078] The present disclosure provides the use of the monoclonal or polyclonal anti-anti-anti- graft or anti-anti-graft antibodies antibodies to reduce the risk of transplant rejection in a recipient by administering to the recipient animal an effective amount of monoclonal or polyclonal anti-anti-anti-graft or anti-anti-graft antibodies in a non-immunogenic form.
[0079] If desired, and not counter-productive, administration of the compound according to the invention may be combined with more traditional and existing therapies for treating or preventing the disorder e.g. transplant rejection.
[0080] An "effective amount" of a compound according to the invention refers to a non- immunogenic amount, for the number and periods of time necessary, to achieve the desired result; that is, selective suppression of the recipient's immune response to the donor graft. An effective amount of the compound may vary according to factors such as the health, age, sex and weight of the individual, and the species of the donor and recipient animals. The effective amount may be adjusted to provide the optimum result. It is preferred that the amount be between about 1 ng and about 10 μg of the monoclonal or polyclonal anti-anti-anti-graft or anti-anti-graft antibody per kilogram per administration to the recipient, or alloimmune immunogen absorbed serum containing approximately the same total amount of anti-anti- graft IgG. For example, about 1 μg of the monoclonal or polyclonal anti-anti-anti-graft or
anti-anti-graft antibody per kilogram per administration to the recipient, or alloimmune immunogen absorbed serum containing approximately the same total amount of IgG.
[0081] In part, the present disclosure provides a composition comprising the monoclonal or polyclonal anti-anti-anti-graft or anti-anti-graft antibody in combination with a
pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier will depend on the mode of administration of the compound. The carrier may, for example, be non- immunogenic. Suitable carriers are those known in the art for use in such modes of administration.
[0082] The pharmaceutical compositions may be formulated by means known in the art and their mode of administration.
[0083] The pharmaceutical composition may comprise anti-anti-anti-MHC monoclonal or polyclonal antibodies or fragments of antibodies in combination with a pharmaceutically acceptable carrier.
[0084] The dose of the pharmaceutical composition may be determined by the skilled practitioner. It is preferred that each dose contain between about 10 ng and about 10 μg of the monoclonal anti-anti-anti-graft antibody per kilogram weight of the recipient. For example, about 1 μg of the monoclonal or polyclonal anti-anti-anti-graft or anti-anti-MHC antibody per kilogram weight of the recipient per dose, or alloimmune immunogen absorbed serum containing the same total amount of IgG.
[0085] The present invention further discloses a kit comprising a pharmaceutical composition of the monoclonal or polyclonal anti-anti-anti-MHC or anti-anti-MHC antibody with a pharmaceutically acceptable carrier together with instructions for administration to recipients of donor tissue.
[0086] In part, the present disclosure further provides a method of supplying monoclonal or polyclonal anti-anti-anti-MHC or anti-anti-MHC antibodies, the method comprising: a) receiving input parameters, said parameters comprising a sample of lymphocytes from a tissue donor and a delivery location; b) obtaining, based on the input parameters, an appropriate monoclonal or
polyclonal anti-anti-anti-MHC or anti-anti-MHC antibodies for facilitating the transplantation of tissue from said donor to a recipient; and
c) distributing said monoclonal or polyclonal anti-anti-anti-MHC or anti-anti-MHC antibodies to the delivery location.
[0087] The present method can be used also for non-human vertebrates. For example, the method may include the production of monoclonal or polyclonal anti-anti-anti-graft or anti- anti-graft antibodies suitable for using dogs as donors for dogs that are in need of an organ transplant, and the production of monoclonal or polyclonal anti-anti-anti-graft or anti-anti- graft antibodies suitable for using cats as donors for cats.
[0088] The present method comprises distributing the antibodies to a delivery location. The distribution may be done by any suitable means. Given the time sensitivity of organ donation it is preferred that the distribution is performed in an expeditious manner.
[0089] In part, the present disclosure provides a method, use, pharmaceutical composition and kit for preventing rejection of a transplanted tissue from a donor. The present disclosure provides a highly efficacious way of attaining selective suppression of the recipient's immune system. In certain embodiments administration of monoclonal or polyclonal anti-anti-anti- graft or anti-anti-graft antibodies obtained from an immunized donor can specifically and robustly suppress the immune response of the recipient against the foreign antigens of the transplanted graft, without comprising the immune response of the recipient against other antigens. Further, the risk of adverse effects associated with immunosuppressant drugs currently used in preventing graft rejection is reduced. Transplantation of organs, tissues or cells from donors of a species different from that of the recipient may also be used as a long- term, sustainable therapy for organ or tissue failure.
[0090] It is contemplated that any embodiment discussed in this specification can be implemented or combined with respect to any other embodiment, method, composition or aspect of the invention, and vice versa.
[0091] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art to which this invention belongs. Unless otherwise specified, all patents, applications, published applications and other publications referred to herein are incorporated by reference in their entirety. If a definition set forth in this section is contrary to or otherwise inconsistent with a definition set forth in the patents, applications, published applications and other publications that are herein incorporated by reference, the definition set forth in this section prevails over the definition
that is incorporated herein by reference. Citation of references herein is not to be construed nor considered as an admission that such references are prior art to the present invention.
[0092] Use of examples in the specification, including examples of terms, is for illustrative purposes only and is not intended to limit the scope and meaning of the embodiments of the invention herein. Numeric ranges are inclusive of the numbers defining the range. In the specification, the word "comprising" is used as an open-ended term, substantially equivalent to the phrase "including, but not limited to," and the word "comprises" has a corresponding meaning.
[0093] The invention includes all embodiments, modifications and variations substantially as hereinbefore described and with reference to the examples and figures. It will be apparent to persons skilled in the art that a number of variations and modifications can be made without departing from the scope of the invention as defined in the claims. Examples of such modifications include the substitution of known equivalents for any aspect of the invention in order to achieve the same result in substantially the same way.
[0094] The present invention will be further illustrated in the following examples. However it is to be understood that these examples are for illustrative purposes only, and should not be used to limit the scope of the present invention in any manner.
EXAMPLES
[0095] Example 1. A method for producing anti-anti-anti-MHC antibodies using the immune systems of two animals P and Q, whereby the anti-anti-anti-MHC antibodies are believed to be functionally the equivalent of anti-IJp antibodies in mice. The method comprises the steps of: a. an animal P is multiply immunized with lymphocytes of an animal Q; b. an animal Q is multiply immunized with lymphocytes of an animal P;
c. IgG is obtained from the said immunized animal P is absorbed using Q
lymphocytes, producing anti-anti-(MHC P)IgG; d. hybridomas are produced using B lymphocytes of the the immunized animal Q; e. hybridomas from step d. are selected that have V regions that bind to the V
regions of the anti-anti-(MHC P)IgG antibodies obtained in step c. and do not
bind to MHC antigens of P, and are consequently anti-anti-anti-(MHC) antibodies;
f. the hybridomas selected in step e. are used to make the monoclonal anti-anti-anti- (MHC P) antibodies.
[0096] Example 2. A method for producing monoclonal anti-anti-anti-MHC antibodies, whereby the anti-anti-anti-MHC antibodies are believed to be functionally the equivalent of anti-IJp antibodies in mice and are believed to bind to the HIV antigens gpl20, gp41 and p24. The method comprises the steps of: a. an animal Q is multiply immunized with lymphocytes of an animal P; b. lymphocytes of the immunized animal Q are used to make hybridomas; c. the hybridomas are used to produce monoclonal antibodies, which are assayed for binding to HIV antigens; d. the monoclonal antibodies that bind to the said HIV antigens are believed to be the desired anti-anti-anti-MHC antibodies.
[0097] Example 3. The use of monoclonal anti-anti-anti-MHC antibodies in the treatment of a patient with an autoimmune disease comprising the administration of monoclonal anti-anti- anti-(patient MHC) antibodies in non-immunogenic form and in non-immunogenic amounts and a pharmaceutically acceptable carrier.
[0098] Example 4. The use of monoclonal anti-anti-anti-MHC antibodies in the treatment of a patient with a cancer comprising the administration of monoclonal anti-anti-anti-(patient MHC) antibodies in non-immunogenic form and in non-immunogenic amounts and a pharmaceutically acceptable carrier.
[0099] Example 5. The use of monoclonal anti-anti-anti-MHC antibodies in the treatment of the recipient of an organ transplant comprising the administration to the recipient of monoclonal anti-anti-anti-(donor MHC) antibodies in non-immunogenic form and in non- immunogenic amounts and a pharmaceutically acceptable carrier, where the donor is the donor of the organ, starting at the time of a skin graft, and at intervals thereafter, until the skin graft is stably accepted. Then the recipient is believed to be tolerant to tissue of the organ donor, and the organ transplant is carried out. Additional administrations of the anti-anti-anti- donor antibodies may optionally be given following the transplantation of the organ from the donor to the recipient.
Claims
A monoclonal antibody that specifically binds to the variable region of an anti-anti- MHC antibody.
A monoclonal antibody according to claim 1 wherein the monoclonal antibody and the anti-anti-MHC antibody are derived from conversely alloimmune animals.
A monoclonal antibody according to claim 1 or 2 that also binds to the HIV antigens gpl20, gp41 , p24, or a combination thereof.
A method for producing a hydridoma capable of producing monoclonal anti-anti-anti- MHC antibodies, said method comprising: a. Immunizing an animal P with lymphocytes of an animal Q; b. Immunizing animal Q with lymphocytes of animal P; c. Obtaining IgG from the immunized animal P; d. Treating said IgG with Q lymphocytes to absorb out anti-(MHC Q) and anti- anti-anti-(MHC Q) antibodies and thus to produce IgG enriched with anti-anti- (MHC P) IgG; e. Producing hybridomas using B lymphocytes of the immunized animal Q; f. Selecting hybridomas that make monoclonal anti-anti-anti-(P MHC) antibodies i.e. have V regions that bind to the V regions of the anti-anti-(MHC P)IgG antibodies of step d. and do not substantially bind to P MHC antigens; and g. Optionally producing monoclonal anti-anti-anti-(MHC P) antibodies from said hydridomas.
A method for producing hydridomas capable of producing monoclonal anti-anti-anti- MHC antibodies comprising the steps of:
a. Immunizing an animal Q with lymphocytes of an animal P; b. Making hydridomas from lymphocytes of the immunized animal Q; c. Producing antibodies from said hybridomas; d. Assaying said antibodies for their binding to the HIV antigens gpl20, gp41 and/or p24; and e. Optionally, confirming the anti-anti-anti-MHC specificity by testing for
binding to anti-anti-P antibodies and/or lack of binding to P MHC antigens.
6. The use of the monoclonal anti-anti-anti-MHC antibodies of claims 1 to 3 in the
treatment of a vertebrate animal (X) having or at risk of developing a degenerative disease comprising the administration to said animal of an effective, non- immunogenic, amount of monoclonal anti-anti-anti-(X MHC) antibodies.
7. The use of claim 6 when en the degenerative disease is an autoimmune disease.
8. The use of claim 6 wherein the degenerative disease is a cancer.
9. The use of claim 6, in which the vertebrate (X) is administered more than one dose of monoclonal anti-anti-anti-(X MHC) antibodies.
10. The use of claim 6, wherein about 10 ng to about 10 μg of the anti-anti-anti-donor antibodies per kilogram of the vertebrate is administered per dose.
1 1. The use of monoclonal anti-anti-anti-MHC antibodies in the treatment of the recipient of a tissue transplant, said use comprising the administration to the recipient an effective amount of monoclonal anti-anti-anti-(donor MHC) antibodies in non- immunogenic form and a pharmaceutically acceptable carrier, where the donor is the prospective tissue donor.
12. The use of claim 1 1, wherein said recipient animal and said donor animal are of the same species.
13. The use of claim 1 1, wherein said recipient animal and said donor animal are different species.
14. The use of claim 11 , wherein said monoclonal anti-anti-anti-(donor MHC) antibodies are administered to the recipient animal at the time of, and/or following
transplantation of tissue from the donor animal to the recipient animal.
15. The use of claim 1 1 , wherein said monoclonal anti-anti-anti-(donor MHC) antibodies are administered to the recipient prior to and/or at the time of and/or following transplantation of tissue from the donor animal to the recipient animal.
16. The use of claim 11 , wherein about 10 ng to about 10 μg of the anti-anti-anti-donor antibodies per kilogram of the recipient is administered per dose.
17. A kit comprising:
(a) a composition comprising monoclonal anti-anti-anti-MHC antibodies and a
pharmaceutically acceptable carrier; and
(b) instructions for use in an animal.
18. A use for monoclonal anti-anti-anti-MHC antibodies in inducing mutual
transplantation tolerance between two vertebrates "A" and "B" comprising administering anti-anti-anti-(B MHC) antibodies to A and applying a B skin graft to A; administering anti-anti-anti-(A MHC) antibodies to B and applying an A skin graft to B; and assessing when the skin grafts are stably accepted as an indication of transplantation tolerance.
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161429708P | 2011-01-04 | 2011-01-04 | |
US201161429718P | 2011-01-04 | 2011-01-04 | |
US61/429,708 | 2011-01-04 | ||
US61/429,718 | 2011-01-04 | ||
US201161431778P | 2011-01-11 | 2011-01-11 | |
US61/431,778 | 2011-01-11 | ||
US201161488618P | 2011-05-20 | 2011-05-20 | |
US61/488,618 | 2011-05-20 | ||
US201161492723P | 2011-06-02 | 2011-06-02 | |
US61/492,723 | 2011-06-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012092663A1 true WO2012092663A1 (en) | 2012-07-12 |
Family
ID=46457163
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2012/000004 WO2012092665A1 (en) | 2011-01-04 | 2012-01-04 | Method for facilitating tissue transplantation |
PCT/CA2012/000003 WO2012092664A1 (en) | 2011-01-04 | 2012-01-04 | Monoclonal anti-anti-mhc antibodies and uses thereof |
PCT/CA2012/000002 WO2012092663A1 (en) | 2011-01-04 | 2012-01-04 | Monoclonal anti-anti-anti-mhc antibodies and uses thereof |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2012/000004 WO2012092665A1 (en) | 2011-01-04 | 2012-01-04 | Method for facilitating tissue transplantation |
PCT/CA2012/000003 WO2012092664A1 (en) | 2011-01-04 | 2012-01-04 | Monoclonal anti-anti-mhc antibodies and uses thereof |
Country Status (1)
Country | Link |
---|---|
WO (3) | WO2012092665A1 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0700297B1 (en) * | 1993-05-24 | 2002-07-31 | Ximerex, Inc. | Surrogate tolerogenesis for the development of tolerance to xenografts |
US5560911A (en) * | 1993-10-12 | 1996-10-01 | Oklahoma Medical Research Foundation | Method of inhibiting acute complement mediated cytotoxicity with anti-idiotypic antibodies |
-
2012
- 2012-01-04 WO PCT/CA2012/000004 patent/WO2012092665A1/en active Application Filing
- 2012-01-04 WO PCT/CA2012/000003 patent/WO2012092664A1/en active Application Filing
- 2012-01-04 WO PCT/CA2012/000002 patent/WO2012092663A1/en active Application Filing
Non-Patent Citations (3)
Title |
---|
BURLINGHAM W.J. ET AL.: "HLA (A*0201 ) Mimicry by Anti-Idiotypic Monoclonal Antibodies", J. IMMUNOL., vol. 161, no. 12, 15 December 1998 (1998-12-15), pages 6705 - 14, XP002197555 * |
KION T.A. ET AL.: "Anti-HIV and Anti-anti-MHC Antibodies in Alloimmune and Autoimmune Mice", SCIENCE, vol. 253, no. 5024, 6 September 1991 (1991-09-06), pages 1138 - 40 * |
LI H. ET AL.: "Identification of an N-Linl:ed Glvcosvlation in the C4 Region of HIV-I Envelope gp 120 That Is Critical for Recognition of Neighboring CD4 T Cell Epitopes", J. HNMUNOL., vol. 180, no. 6, 15 March 2008 (2008-03-15), pages 40I 1 - 21. 1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2012092665A1 (en) | 2012-07-12 |
WO2012092664A1 (en) | 2012-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hotchkiss et al. | Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor | |
Cobbold et al. | Reprogramming the immune system for peripheral tolerance with CD4 and CD8 monoclonal antibodies | |
Goronzy et al. | Long-term humoral unresponsiveness in vivo, induced by treatment with monoclonal antibody against L3T4. | |
Matsuda et al. | Human platelets can initiate T cell-dependent contact sensitivity through local serotonin release mediated by IgE antibodies. | |
KR20190130624A (en) | Alternative to cytotoxic preconditioning before cellular immunotherapy | |
Eisenberg et al. | T cells, murine chronic graft-versus-host disease and autoimmunity | |
US20210040230A1 (en) | Methods and Compositions for the Treatment of Autoimmune and Inflammatory Diseases | |
JP2013539352A5 (en) | ||
Allison | Mechanisms of tolerance and autoimmunity | |
JPH04505919A (en) | Monoclonal antibodies to induce tolerance | |
Jordan et al. | Immunomodulatory actions of intravenous immunoglobulin (IVIG): potential applications in solid organ transplant recipients | |
WO2012092663A1 (en) | Monoclonal anti-anti-anti-mhc antibodies and uses thereof | |
Roehnisch et al. | Chemically linked phage idiotype vaccination in the murine B cell lymphoma 1 model | |
Sinclair et al. | The immunoregulatory apparatus and autoimmunity | |
Saeki et al. | Characterization of" regulatory" idiotope-specific T cell clones to a monoclonal anti-idiotypic antibody mimicking a tumor-associated antigen (TAA). | |
Richman et al. | Treatment principles in the management of autoimmune myasthenia gravis | |
Lemke | Antigen Receptor− Intrinsic Non-Self: The Key to Understanding Regulatory Lymphocyte− Mediated Idiotypic Control of Adaptive Immune Responses | |
Kotzin et al. | Total lymphoid irradiation | |
Stocks et al. | Lupus-prone mice resist immune regulation and transplant tolerance induction | |
Borel et al. | Oligonucleotide linked to human gammaglobulin specifically diminishes anti-DNA antibody formation in cultured lymphoid cells from patients with systemic lupus erythematosus. | |
Kirk et al. | American society of transplantation symposium on B cells in transplantation: harnessing humoral immunity from rodent models to clinical practice | |
Sanfilippo et al. | Antibody and complement in graft rejection | |
Zanetti et al. | Self-recognition, auto-immunity, and internal images | |
Uemura et al. | Immunization with anti‐idiotype monoclonal antibodies bearing the internal image of the renal‐cell carcinoma‐associated antigen G250 induces specific cellular immune responses | |
Chatenoud | The use of CD3-specific antibodies in autoimmune diabetes: a step toward the induction of immune tolerance in the clinic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12732240 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12732240 Country of ref document: EP Kind code of ref document: A1 |